donepezil has been researched along with Cognition Disorders in 253 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to explore which tests and their measures are able to detect cognitive change after a single dose of donepezil in Alzheimer disease (AD) patients." | 9.20 | Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease. ( Kaubrys, G; Kuzmickienė, J, 2015) |
| "Adjunctive treatment with donepezil improves cognition in patients with schizophrenia who are stabilized on atypical antipsychotics." | 9.14 | Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. ( Chung, YC; Kim, KW; Lee, CR; Park, TW; Yang, KH, 2009) |
| "The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)." | 9.14 | Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010) |
| "To determine whether donepezil is effective in enhancing cognitive functioning and instrumental activities of daily living (IADLs) in older adults with bipolar disorder." | 9.13 | A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. ( Butters, MA; Chisholm, D; Gildengers, AG; Mulsant, BH; Reynolds, CF, 2008) |
| "Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment." | 9.13 | Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. ( Chabriat, HS; Dichgans, M; Markus, HS; Moline, M; Posner, H; Salloway, S; Verkkoniemi, A; Wang, Q, 2008) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 9.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia." | 9.12 | Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study. ( Kadlecová, E; Lenderová, Z; Pérez, M; Pytela, O; Tůma, I; Zemanová, M, 2006) |
| " We studied whether donepezil improves chorea, cognition, and quality of life (QoL) in HD." | 9.12 | Effect of donepezil on motor and cognitive function in Huntington disease. ( Bernard, BA; Cubo, E; Jaglin, JA; Leurgans, SE; Shannon, KM; Tracy, D; Wuu, J, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 9.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "To determine whether an acetylcholinesterase inhibitor, such as donepezil, would improve memory or other cognitive/psychological functions in epilepsy patients with subjective memory complaints." | 9.12 | A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy. ( Choi, H; Hamberger, MJ; Hirsch, LJ; Palmese, CA; Scarmeas, N; Weintraub, D, 2007) |
| "To examine whether the presence of domain-specific cognitive impairments would predict a response to donepezil medication in patients with mild-to-moderate Alzheimer disease (AD)." | 9.12 | Cognitive predictors of donepezil therapy response in Alzheimer disease. ( Bergman, H; Chertkow, H; Murtha, S; Phillips, N; Saumier, D; Whitehead, V, 2007) |
| "To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)." | 9.12 | Donepezil preserves cognition and global function in patients with severe Alzheimer disease. ( Black, SE; Doody, R; Jambor, KM; Li, H; McRae, T; Perdomo, CA; Richardson, S; Sun, Y; Xu, Y, 2007) |
| "Similar to other studies using acetylcholinesterase inhibitors in more heterogeneous and symptomatic groups of patients with schizophrenia, donepezil does not appear to enhance cognitive abilities." | 9.12 | No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. ( Bilker, W; Gur, RC; Gur, RE; Kohler, CG; Kujawski, E; Martin, EA, 2007) |
| "This study investigated the efficacy of the cholinesterase agent donepezil in the treatment of menopause-related cognitive loss." | 9.12 | A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss. ( Devi, G; Khosrowshahi, L; Laakso, UK; Massimi, S; Schultz, S, 2007) |
| "Our aim was to examine if donepezil administered to stable, medicated outpatients with schizophrenia improves cognition and psychopathology." | 9.11 | Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. ( Cather, C; Deckersbach, T; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Herz, L, 2005) |
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 9.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "Our goal in this study was to determine whether donepezil, an acetylcholinesterase inhibitor, would improve cognitive functioning in 19 subjects with Down syndrome and no dementia." | 9.10 | Effects of donepezil on cognitive functioning in Down syndrome. ( Chicoine, B; Chong, G; Fahey, C; Gitelman, D; Johnson, N, 2003) |
| "The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option." | 8.89 | Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. ( Henderson, DC; Thakurathi, N; Vincenzi, B, 2013) |
| "The results of this study suggested that early induction of donepezil treatment was necessary when apparent cognitive decline was identified during the treatment of geriatric depression." | 7.83 | Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression. ( Hoshino, R; Inoue, J; Ishida, W; Nojima, H; Okamoto, N, 2016) |
| " In the present study, we reported that donepezil, a cholinesterase inhibitor, improved transient global cerebral ischemia-induced spatial memory impairment in gerbils." | 7.78 | Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. ( Cai, J; Cao, Y; Chen, T; Guo, F; Mao, X; Min, D; Shaw, C; Wang, L; Wu, K; Xie, N; Zhu, S, 2012) |
| "All bipolar disordered patients in a private practice setting treated with donepezil for memory problems were analyzed." | 7.74 | Is donepezil useful for improving cognitive dysfunction in bipolar disorder? ( Kelly, T, 2008) |
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 7.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| "A case of hypnopompic hallucinations associated with donepezil is described." | 7.70 | Hypnopompic hallucinations with donepezil. ( Gray, R; Yorston, GA, 2000) |
| "Some breast cancer survivors report cognitive difficulties greater than 1 year after chemotherapy." | 6.82 | A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. ( Balcueva, EP; Case, LD; Griffin, L; Groteluschen, DL; Lawrence, JA; Lesser, GJ; Naughton, MJ; Rapp, SR; Samuel, TA; Shaw, EG, 2016) |
| "Donepezil has been proven effective in the treatment of Alzheimer's disease and vascular dementia." | 6.76 | Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study. ( Chang, WH; Kim, YH; Lee, PK; Ohn, SH; Park, CH; Park, YH, 2011) |
| "Donepezil was safe and well-tolerated but was not effective compared with placebo as a cotreatment for the improvement of cognitive impairment in this patient population." | 6.73 | Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. ( Buchanan, RW; Goldman, R; Kane, JM; Keefe, RS; Li, C; Malhotra, AK; Meltzer, HY; Murthy, A; Sovel, M, 2008) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 5.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "Donepezil may ameliorate visual hallucinations in PD patients, but controlled, double-blind trials are necessary to further clarify the effect of this drug on VHs in PD." | 5.32 | The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. ( Inoue, K; Kono, Y; Kurita, A; Ochiai, Y; Suzuki, M, 2003) |
| "Delirium is a common complication of dementia and may produce considerable morbidity." | 5.30 | Donepezil improves symptoms of delirium in dementia: implications for future research. ( Burke, WJ; Roccaforte, WH; Wengel, SP, 1998) |
| " Significant improvements were observed on the Alzheimer's Disease Assessment Scale-cognitive component-Japanese version and the Neuropsychiatric Inventory depression scores of patients who received the combined therapy with donepezil and NYT (Alzheimer's Disease Assessment Scale-cognitive component-Japanese version, 12 months: P < 0." | 5.22 | Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation. ( Arita, R; Asou, H; Honda, M; Kishi, T; Komatsu, Y; Kudoh, C; Mimura, M, 2016) |
| "The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to explore which tests and their measures are able to detect cognitive change after a single dose of donepezil in Alzheimer disease (AD) patients." | 5.20 | Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease. ( Kaubrys, G; Kuzmickienė, J, 2015) |
| "Adjunctive treatment with donepezil improves cognition in patients with schizophrenia who are stabilized on atypical antipsychotics." | 5.14 | Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. ( Chung, YC; Kim, KW; Lee, CR; Park, TW; Yang, KH, 2009) |
| "To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship." | 5.14 | Donepezil delays progression to AD in MCI subjects with depressive symptoms. ( Cummings, JL; Edland, SD; Lu, PH; Petersen, RC; Teng, E; Tingus, K, 2009) |
| "The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)." | 5.14 | Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010) |
| "To determine whether donepezil is effective in enhancing cognitive functioning and instrumental activities of daily living (IADLs) in older adults with bipolar disorder." | 5.13 | A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. ( Butters, MA; Chisholm, D; Gildengers, AG; Mulsant, BH; Reynolds, CF, 2008) |
| "Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment." | 5.13 | Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. ( Chabriat, HS; Dichgans, M; Markus, HS; Moline, M; Posner, H; Salloway, S; Verkkoniemi, A; Wang, Q, 2008) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 5.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia." | 5.12 | Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study. ( Kadlecová, E; Lenderová, Z; Pérez, M; Pytela, O; Tůma, I; Zemanová, M, 2006) |
| " We studied whether donepezil improves chorea, cognition, and quality of life (QoL) in HD." | 5.12 | Effect of donepezil on motor and cognitive function in Huntington disease. ( Bernard, BA; Cubo, E; Jaglin, JA; Leurgans, SE; Shannon, KM; Tracy, D; Wuu, J, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 5.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia." | 5.12 | Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. ( Clark, CM; DeCarli, C; Frisoni, GB; Grundman, M; Harvey, D; Jack, CR; Jin, S; Petersen, RC; Scheltens, P; Thal, LJ, 2007) |
| "To determine whether an acetylcholinesterase inhibitor, such as donepezil, would improve memory or other cognitive/psychological functions in epilepsy patients with subjective memory complaints." | 5.12 | A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy. ( Choi, H; Hamberger, MJ; Hirsch, LJ; Palmese, CA; Scarmeas, N; Weintraub, D, 2007) |
| "To examine whether the presence of domain-specific cognitive impairments would predict a response to donepezil medication in patients with mild-to-moderate Alzheimer disease (AD)." | 5.12 | Cognitive predictors of donepezil therapy response in Alzheimer disease. ( Bergman, H; Chertkow, H; Murtha, S; Phillips, N; Saumier, D; Whitehead, V, 2007) |
| "To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)." | 5.12 | Donepezil preserves cognition and global function in patients with severe Alzheimer disease. ( Black, SE; Doody, R; Jambor, KM; Li, H; McRae, T; Perdomo, CA; Richardson, S; Sun, Y; Xu, Y, 2007) |
| "Similar to other studies using acetylcholinesterase inhibitors in more heterogeneous and symptomatic groups of patients with schizophrenia, donepezil does not appear to enhance cognitive abilities." | 5.12 | No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. ( Bilker, W; Gur, RC; Gur, RE; Kohler, CG; Kujawski, E; Martin, EA, 2007) |
| "This study investigated the efficacy of the cholinesterase agent donepezil in the treatment of menopause-related cognitive loss." | 5.12 | A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss. ( Devi, G; Khosrowshahi, L; Laakso, UK; Massimi, S; Schultz, S, 2007) |
| "Our aim was to examine if donepezil administered to stable, medicated outpatients with schizophrenia improves cognition and psychopathology." | 5.11 | Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. ( Cather, C; Deckersbach, T; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Herz, L, 2005) |
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 5.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "Our goal in this study was to determine whether donepezil, an acetylcholinesterase inhibitor, would improve cognitive functioning in 19 subjects with Down syndrome and no dementia." | 5.10 | Effects of donepezil on cognitive functioning in Down syndrome. ( Chicoine, B; Chong, G; Fahey, C; Gitelman, D; Johnson, N, 2003) |
| " Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation." | 4.93 | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. ( Barrantes, FJ; Peralta, MC; Perez-Lloret, S, 2016) |
| "The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option." | 4.89 | Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. ( Henderson, DC; Thakurathi, N; Vincenzi, B, 2013) |
| "A literature search of MEDLINE (1950-September 2011) was conducted, using the search term depression in combination with cholinesterase inhibitor, donepezil, galantamine, or rivastigmine." | 4.88 | Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. ( Gray, SL; McDermott, CL, 2012) |
| "BACKGROUND The aim of this study was to investigate the effects of oxygen and cholinesterase inhibitor (donepezil) therapy on dementia in patients with age-exacerbated chronic obstructive pulmonary disease (COPD) in China's northwestern high-altitude area." | 3.88 | Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area. ( Li, H; Mei, L; Wang, D; Wang, M; Wu, S; Zhang, H, 2018) |
| "The results of this study suggested that early induction of donepezil treatment was necessary when apparent cognitive decline was identified during the treatment of geriatric depression." | 3.83 | Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression. ( Hoshino, R; Inoue, J; Ishida, W; Nojima, H; Okamoto, N, 2016) |
| " In the present study, we reported that donepezil, a cholinesterase inhibitor, improved transient global cerebral ischemia-induced spatial memory impairment in gerbils." | 3.78 | Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. ( Cai, J; Cao, Y; Chen, T; Guo, F; Mao, X; Min, D; Shaw, C; Wang, L; Wu, K; Xie, N; Zhu, S, 2012) |
| "All bipolar disordered patients in a private practice setting treated with donepezil for memory problems were analyzed." | 3.74 | Is donepezil useful for improving cognitive dysfunction in bipolar disorder? ( Kelly, T, 2008) |
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 3.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| "A case of hypnopompic hallucinations associated with donepezil is described." | 3.70 | Hypnopompic hallucinations with donepezil. ( Gray, R; Yorston, GA, 2000) |
| "Fatigue and neurodegeneration of Alzheimer's disease could share common brain signatures (i." | 3.01 | Fatigue in Alzheimer's disease: biological basis and clinical management-a narrative review. ( Angioni, D; de Souto Barreto, P; Delrieu, J; Ousset, PJ; Raffin, J, 2023) |
| "Some breast cancer survivors report cognitive difficulties greater than 1 year after chemotherapy." | 2.82 | A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. ( Balcueva, EP; Case, LD; Griffin, L; Groteluschen, DL; Lawrence, JA; Lesser, GJ; Naughton, MJ; Rapp, SR; Samuel, TA; Shaw, EG, 2016) |
| "Treatment with donepezil did not significantly improve the overall composite score, but it did result in modest improvements in several cognitive functions, especially among patients with greater pretreatment impairments." | 2.80 | Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. ( Case, LD; Chan, MD; Edenfield, WJ; Falchuk, SC; Giguere, JK; Loghin, ME; Moore, DF; Naughton, MM; Peiffer, A; Piephoff, JV; Rapp, SR; Shaw, EG; Stieber, VW, 2015) |
| " 25 patients (seven taking placebo and 18 taking idalopirdine) discontinued treatment because of adverse events, the difference between groups being mainly due to asymptomatic transient increases in transaminase concentrations in some idalopirdine-treated patients." | 2.79 | Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. ( Colding-Jørgensen, E; Wilkinson, D; Windfeld, K, 2014) |
| "Cotreatment with donepezil (10 mg) significantly ameliorated scopolamine-induced impairment at the 2-h time point (Cohen's d = 0." | 2.78 | Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults. ( Harel, BT; Maruff, P; Pietrzak, RH; Snyder, PJ, 2013) |
| "Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses." | 2.78 | Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. ( Christensen, D; Cummings, J; Doody, R; Fain, R; Farlow, M; Liu, L; Mackell, J; Sabbagh, M, 2013) |
| "Drug development is a high-risk and high failure enterprise, and studies that provide an early read on the pharmacodynamic activity of novel compounds could save time and money, increasing the efficiency of the drug development process." | 2.77 | The scopolamine model as a pharmacodynamic marker in early drug development. ( Abi-Saab, W; Baker, JD; Lenz, RA; Locke, C; Mohler, EG; Rueter, LE; Saltarelli, MD; Wesnes, K, 2012) |
| "Progressive neurodegeneration in Alzheimer's disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD." | 2.77 | The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design. ( Andersen, F; Engstad, TA; Halvorsen, DS; Straume, B; Viitanen, M; Wilsgaard, T, 2012) |
| "Donepezil has been proven effective in the treatment of Alzheimer's disease and vascular dementia." | 2.76 | Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study. ( Chang, WH; Kim, YH; Lee, PK; Ohn, SH; Park, CH; Park, YH, 2011) |
| " Adverse events (AEs) were recorded throughout." | 2.75 | Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. ( Doody, RS; Ferris, S; Gao, J; Goldman, R; Murthy, AK; Salloway, S, 2010) |
| "More donepezil-treated subjects (18." | 2.74 | Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. ( Doody, RS; Ferris, SH; Goldman, R; Murthy, AK; Salloway, S; Sun, Y; Watkins, WE; Xu, Y, 2009) |
| "Donepezil-treated participants experienced a 14-point greater improvement in the FIM-motor score compared to either galantamine-treated participants or the historical comparator group (repeated measures mixed model, group x time interaction p < 0." | 2.73 | An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. ( Butters, M; Cabacungan, L; Dew, MA; Koenig, K; Lenze, EJ; Mulsant, BH; Munin, MC; Penrod, L; Pollock, BG; Reynolds, CF; Skidmore, E; Whyte, EM, 2008) |
| "More donepezil-treated than placebo-treated patients experienced diarrhea, but other adverse effects and safety measures did not differ between groups." | 2.73 | Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial. ( Babyak, MA; Blumenthal, JA; Doraiswamy, PM; Hennig, T; Mathew, JP; Newman, MF; Trivedi, R; White, WD, 2007) |
| " Tolerability can be increased by use of flexible dosing and efficacy is likely to be enhanced by increasing the length of the trial from six to 12 months and by enriching the sample with subjects more likely to decline during the trial." | 2.73 | Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI. ( Correia, S; Richardson, S; Salloway, S, 2008) |
| "Donepezil was safe and well-tolerated but was not effective compared with placebo as a cotreatment for the improvement of cognitive impairment in this patient population." | 2.73 | Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. ( Buchanan, RW; Goldman, R; Kane, JM; Keefe, RS; Li, C; Malhotra, AK; Meltzer, HY; Murthy, A; Sovel, M, 2008) |
| "To describe a cohort of patients with Alzheimer's disease from a whole city population treated with donepezil, and to analyse outcomes over 4 years." | 2.73 | Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. ( Benbow, S; Clark, M; Grizzell, M; Jolley, D; Lyle, S; Willmott, S, 2008) |
| "Delays in the diagnosis of Alzheimer's disease, and, therefore, delays in treatment, may have a detrimental effect on a patient's long-term well-being." | 2.72 | 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. ( Engedal, K; Haglund, A; Schindler, R; Soininen, H; Verhey, F; Waldemar, G; Wetterholm, AL; Wimo, A; Winblad, B; Zhang, R, 2006) |
| "All 24 patients had a primary brain tumor, mostly low-grade glioma." | 2.72 | Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. ( D'Agostino, RB; Lovato, J; Naughton, MJ; Rapp, SR; Robbins, ME; Rosdhal, R; Shaw, EG, 2006) |
| "Current outcome measures for Alzheimer's disease (AD) drugs have been criticized as insufficiently patient-centred." | 2.72 | Verbal repetition in patients with Alzheimer's disease who receive donepezil. ( Asp, E; Cloutier, F; Cook, C; Dei, DW; Fay, S; Fisk, J; Robertson, ML; Rockwood, K, 2006) |
| "6 %)treatment was withdrawn because of mostly gastrointestinal adverse events." | 2.71 | Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. ( Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E, 2004) |
| "More donepezil-treated patients showed improvements in ADAS-cog total scores, in tests of attention and psychomotor speed, and in PGA scores." | 2.71 | Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. ( Ferris, S; Goldman, R; Griesing, T; Kluger, A; Kumar, D; Richardson, S; Salloway, S, 2004) |
| "To characterise the population of Alzheimer's disease patients treated with acetylcholinesterase inhibitors, to analyse effectiveness and drug safety in the clinical practice, and to identify variables that may predict the response to therapy." | 2.71 | A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. ( Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N, 2005) |
| "To understand the treatment goals of Alzheimer's disease (AD) patients, carers, and physicians; to estimate whether clinically important goals are met during treatment with donepezil; and to compare a measure of goal attainment with standard measures used to evaluate AD treatment." | 2.70 | Goal setting and attainment in Alzheimer's disease patients treated with donepezil. ( Fay, S; Graham, JE; Rockwood, K, 2002) |
| "Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living." | 2.70 | Donepezil in the treatment of progressive supranuclear palsy. ( Barbanti, P; Bonifati, V; Colosimo, C; Fabbrini, G; Gasparini, M; Meco, G; Vanacore, N, 2001) |
| "Donepezil is a cholinesterase inhibitor." | 2.58 | Donepezil for dementia due to Alzheimer's disease. ( Birks, JS; Harvey, RJ, 2018) |
| "Donepezil was found to benefit patients in cognition and global functioning." | 2.58 | A review of clinical treatment considerations of donepezil in severe Alzheimer's disease. ( Adlimoghaddam, A; Albensi, BC; Neuendorff, M; Roy, B, 2018) |
| " Acetylcholinesterase inhibitors (AChEIs) aim to provide symptomatic benefit for cognitive decline, however these drugs are not without adverse events (AEs)." | 2.55 | Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. ( Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D, 2017) |
| "People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population." | 2.52 | Pharmacological interventions for cognitive decline in people with Down syndrome. ( Hanratty, J; Livingstone, N; Macdonald, G; McShane, R, 2015) |
| "Alzheimer's disease is the most common cause of dementia in older people." | 2.43 | Donepezil for dementia due to Alzheimer's disease. ( Birks, J; Harvey, RJ, 2006) |
| "Alzheimer's disease is the most common cause of dementia in older people." | 2.42 | Donepezil for dementia due to Alzheimer's disease. ( Birks, JS; Harvey, R, 2003) |
| "Therefore, additional therapies for Alzheimer's disease still need to be developed that include more tolerable agents with alternative mechanisms of action and broader efficacy." | 2.42 | Current treatments for Alzheimer's disease: cholinesterase inhibitors. ( Doody, RS, 2003) |
| "Donepezil does not cause liver toxicity or significant drug interactions and is relatively well-tolerated." | 2.42 | Donepezil: a clinical review of current and emerging indications. ( Rogers, SJ; Román, GC, 2004) |
| " Activities of daily living and social behaviour: On the Instrumental Activity of Daily Living (IADL) scale, there was no statistically significant difference between the groups taking donepezil 5mg per day donepezil and placebo, but the group taking 10 mg of donepezil a day showed benefit compared with placebo There were statistically significant benefit for donepezil at either dosage compared with placebo on the Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)." | 2.42 | Donepezil for vascular cognitive impairment. ( Birks, J; Malouf, R, 2004) |
| "Donepezil (Aricept) is a highly selective acetylcholinesterase inhibitors with a pharmacokinetic profile allowing once-daily dosing." | 2.42 | Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. ( Geldmacher, DS, 2004) |
| "100 of the cases as announcing an Alzheimer's Disease (AD)." | 2.41 | [Mild Cognitive Impairment: potential therapeutics]. ( Allain, H; Belliard, S; Bentue-Ferrer, D; Djemaï, M; Merienne, M; Reymann, JM, 2002) |
| "Alzheimer's disease is the most common cause of dementia and is a primary degenerative disease of the brain of unknown cause." | 2.41 | Donepezil for mild and moderate Alzheimer's disease. ( Birks J, S; Melzer, D, 2000) |
| "Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings." | 2.41 | Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. ( Duttagupta, S; Fillit, HM; Knopman, DS; Lloyd, JR; Max, W; Rice, DP, 2001) |
| "The rapid growth of the world's Alzheimer's disease (AD) population has resulted in a tremendous financial burden on society, a situation exacerbated by the fact that the funding of health and social services faces increasing restrictions in the coming years." | 2.40 | An economic perspective on Alzheimer's disease. ( Trabucchi, M, 1999) |
| " Donepezil (3 mg/kg; po) and sertraline (10 mg/kg; po) dosing was started from D-8 and continued up to D-32." | 1.62 | Development and treatment of cognitive inflexibility in sub-chronic stress-re-stress (SRS) model of PTSD. ( Krishnamurthy, S; Prajapati, SK, 2021) |
| " T-006 improved cognitive ability after long-term administration in two AD mouse models and targeted mitochondrial-related protein alpha-F1-ATP synthase (ATP5A)." | 1.62 | The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease. ( Chen, H; Cheng, J; Guo, B; Huang, C; Su, Z; Sun, Y; Wang, Y; Wu, J; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhu, Z, 2021) |
| " 3xTg-AD mice (10-month-old) were dosed intraperitoneally with 9R (daily 3, 10 or 30 mg/kg) for a month." | 1.56 | 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model. ( Ju, Y; Tam, KY, 2020) |
| " However, a dose-response study evaluating DON after a controlled cortical impact (CCI) injury in rats did not reveal cognitive benefits." | 1.48 | Systemic administration of donepezil attenuates the efficacy of environmental enrichment on neurobehavioral outcome after experimental traumatic brain injury. ( Bondi, CO; Bou-Abboud, CE; Cheng, JP; Day-Cooney, J; Folweiler, KA; Kline, AE; Leary, JB; Memarzadeh, K; Tehranian-DePasquale, R; Yelleswarapu, NK, 2018) |
| "Donepezil was increased from 5 to 10 mg 7-10 days after initiation and maintained until follow-up cognitive assessment." | 1.48 | The effect of donepezil on the cognitive ability early in the course of recovery from traumatic brain injury. ( Brunner, RC; Campbell, KA; Hollis, SD; Kennedy, RE; Lumsden, RA; Novack, TA, 2018) |
| "The clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) subscale change is disputed." | 1.46 | Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. ( Hoffman, D; Howlett, SE; Mitnitski, A; Rockwood, K; Schindler, R, 2017) |
| "Treatment with donepezil or BPCT significantly decreased the prolonged 2nd retention transfer latency and 2nd retention latency time values of the SADM group in the EPM and MWM tests, respectively." | 1.46 | A benzothiazole/piperazine derivative with acetylcholinesterase inhibitory activity: Improvement in streptozotocin-induced cognitive deficits in rats. ( Can, ÖD; Demir Özkay, Ü; Sağlık, BN; Turan, N, 2017) |
| " Demographic variables, quantity and rate of prescriptions, dosage forms and strengths were analyzed." | 1.39 | [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. ( Arizaga, RL; Demey, I; Rojas, G, 2013) |
| "Diagnosing and treating patients with Alzheimer's disease (AD) at an early stage should improve the quality of life of the patient and caregiver." | 1.38 | An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. ( Blume, S; Getsios, D; Hernández, L; Ishak, KJ; Maclaine, G, 2012) |
| "Donepezil was well tolerated among childhood BT survivors who had received substantial prior therapy." | 1.38 | Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: a pilot study. ( Castellino, SM; Flowers, L; Hill, DF; McMullen, KP; Parsons, SK; Shaw, EG; Tooze, JA, 2012) |
| "After carotid stenosis was relieved, the cerebral blood flow values significantly increased, and P300 latency and escape latency in the Morris water-maze were significantly shortened." | 1.37 | Relief of carotid stenosis improves impaired cognition in a rat model of chronic cerebral hypoperfusion. ( Chen, KN; Chun-Qing, Z; Duan, W; Gui, L; Huang, HQ; Zheng, J, 2011) |
| "Treatment with donepezil (1." | 1.37 | Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. ( Alkam, T; Furukawa-Hibi, Y; Greig, NH; Matsuyama, A; Mizoguchi, H; Moussaoui, S; Nagai, T; Nitta, A; Suzuki, K; Yamada, K; Yu, QS, 2011) |
| " The results showed that piperine at all dosage range used in this study significantly improved memory impairment and neurodegeneration in hippocampus." | 1.36 | Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease. ( Chonpathompikunlert, P; Muchimapura, S; Wattanathorn, J, 2010) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 1.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "Hypersexuality in Alzheimer's disease (AD) has been rarely investigated." | 1.35 | Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008) |
| "Since acute and chronic administration of the acetylcholinesterase inhibitors, namely donepezil, improves cognitive functions in patients afflicted by mild to moderate dementia and reverses memory deficits in experimental models of learning and memory, it seemed interesting to assess the effects of chronic donepezil treatment on cognitive functions in adult rats with forebrain cholinergic depletion." | 1.35 | Cognitive performances of cholinergically depleted rats following chronic donepezil administration. ( Cutuli, D; De Bartolo, P; Federico, F; Foti, F; Gelfo, F; Mandolesi, L; Petrosini, L, 2009) |
| "Donepezil was added to their usual treatment for 8 weeks." | 1.33 | Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. ( Bergman, J; Brettholz, I; Dwolatzky, T; Lerner, V, 2005) |
| "Donepezil may ameliorate visual hallucinations in PD patients, but controlled, double-blind trials are necessary to further clarify the effect of this drug on VHs in PD." | 1.32 | The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. ( Inoue, K; Kono, Y; Kurita, A; Ochiai, Y; Suzuki, M, 2003) |
| "Treatment with donepezil and rivastigmine (successively) did not produce the desired benefits." | 1.32 | A case study in the treatment of dementia with Lewy bodies. ( Kaufer, DI, 2004) |
| " A prospective, randomized, placebo-controlled clinical trial with standard timing, dosage and treatment duration is recommended to further evaluate treatment efficacy." | 1.32 | The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes. ( Cornis-Pop, M; Gibellato, M; Jena, T; Lew, H; Seel, R; Silver, T; Walker, W, 2004) |
| "Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance." | 1.32 | Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. ( Buccafusco, JJ; Terry, AV, 2004) |
| "Donepezil has been shown to improve aspects of cognitive functioning in persons with Alzheimer's disease (AD), but its impact on instrumental activities of daily living has received little attention." | 1.31 | Comparison of functional and cognitive donepezil effects in Alzheimer's disease. ( Cullum, CM; Hynan, L; Martin-Cook, K; Saine, K; Svetlik, DA; Weiner, MF, 2002) |
| "Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | 1.30 | [Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998) |
| "Delirium is a common complication of dementia and may produce considerable morbidity." | 1.30 | Donepezil improves symptoms of delirium in dementia: implications for future research. ( Burke, WJ; Roccaforte, WH; Wengel, SP, 1998) |
| "Donepezil has psychotropic properties, and pretreatment behaviors help predict patients' responses to treatment." | 1.30 | The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. ( Barclay, TR; Cummings, JL; Masterman, DM; Mega, MS; O'Connor, SM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (5.93) | 18.2507 |
| 2000's | 141 (55.73) | 29.6817 |
| 2010's | 87 (34.39) | 24.3611 |
| 2020's | 10 (3.95) | 2.80 |
| Authors | Studies |
|---|---|
| Rotstein, A | 1 |
| Levine, SZ | 2 |
| Samara, M | 2 |
| Yoshida, K | 2 |
| Goldberg, Y | 2 |
| Cipriani, A | 2 |
| Iwatsubo, T | 2 |
| Leucht, S | 3 |
| Furukawa, TA | 2 |
| Sagaro, GG | 1 |
| Traini, E | 1 |
| Amenta, F | 1 |
| Angioni, D | 1 |
| Raffin, J | 1 |
| Ousset, PJ | 1 |
| Delrieu, J | 2 |
| de Souto Barreto, P | 1 |
| Guyot, AC | 1 |
| Leuxe, C | 1 |
| Disdier, C | 1 |
| Oumata, N | 1 |
| Costa, N | 1 |
| Roux, GL | 1 |
| Varela, PF | 1 |
| Duchon, A | 1 |
| Charbonnier, JB | 1 |
| Herault, Y | 1 |
| Pavoni, S | 1 |
| Galons, H | 1 |
| Andriambeloson, E | 1 |
| Wagner, S | 1 |
| Meijer, L | 1 |
| Lund, AK | 1 |
| Mabondzo, A | 1 |
| Qi, Y | 1 |
| Jing, H | 1 |
| Cheng, X | 1 |
| Yan, T | 1 |
| Xiao, F | 1 |
| Wu, B | 1 |
| Bi, K | 1 |
| Jia, Y | 1 |
| Semwal, BC | 1 |
| Garabadu, D | 1 |
| Efthimiou, O | 1 |
| Ju, Y | 1 |
| Tam, KY | 1 |
| Prajapati, SK | 1 |
| Krishnamurthy, S | 1 |
| Zhang, G | 2 |
| Wu, J | 1 |
| Huang, C | 1 |
| Cheng, J | 1 |
| Su, Z | 1 |
| Zhu, Z | 1 |
| Yang, X | 1 |
| Guo, B | 1 |
| Wu, L | 1 |
| Zhang, Z | 2 |
| Chen, H | 1 |
| Sun, Y | 5 |
| Wang, Y | 1 |
| Rockwood, K | 4 |
| Howlett, SE | 1 |
| Hoffman, D | 1 |
| Schindler, R | 3 |
| Mitnitski, A | 1 |
| Tung, EE | 1 |
| Litin, SC | 1 |
| Bundrick, JB | 1 |
| Mohammad, D | 1 |
| Chan, P | 1 |
| Bradley, J | 1 |
| Lanctôt, K | 1 |
| Herrmann, N | 1 |
| Demir Özkay, Ü | 1 |
| Can, ÖD | 1 |
| Sağlık, BN | 1 |
| Turan, N | 1 |
| Bondi, CO | 1 |
| Yelleswarapu, NK | 1 |
| Day-Cooney, J | 1 |
| Memarzadeh, K | 1 |
| Folweiler, KA | 1 |
| Bou-Abboud, CE | 1 |
| Leary, JB | 1 |
| Cheng, JP | 1 |
| Tehranian-DePasquale, R | 1 |
| Kline, AE | 1 |
| Fullerton, T | 1 |
| Binneman, B | 1 |
| David, W | 1 |
| Delnomdedieu, M | 1 |
| Kupiec, J | 1 |
| Lockwood, P | 1 |
| Mancuso, J | 1 |
| Miceli, J | 1 |
| Bell, J | 1 |
| Campbell, KA | 1 |
| Kennedy, RE | 1 |
| Brunner, RC | 1 |
| Hollis, SD | 1 |
| Lumsden, RA | 1 |
| Novack, TA | 1 |
| Birks, JS | 2 |
| Harvey, RJ | 2 |
| Arai, H | 1 |
| Hashimoto, N | 1 |
| Sumitomo, K | 1 |
| Takase, T | 1 |
| Ishii, M | 1 |
| Adlimoghaddam, A | 1 |
| Neuendorff, M | 1 |
| Roy, B | 1 |
| Albensi, BC | 1 |
| Kumar, A | 1 |
| Singh, N | 1 |
| Mei, L | 1 |
| Wu, S | 1 |
| Wang, D | 1 |
| Li, H | 2 |
| Zhang, H | 1 |
| Wang, M | 1 |
| Zhang, J | 2 |
| Wang, J | 1 |
| Zhou, GS | 1 |
| Tan, YJ | 1 |
| Tao, HJ | 1 |
| Chen, JQ | 1 |
| Pu, ZJ | 1 |
| Ma, JY | 1 |
| She, W | 1 |
| Kang, A | 1 |
| Zhu, Y | 1 |
| Liu, P | 1 |
| Zhu, ZH | 1 |
| Shi, XQ | 1 |
| Tang, YP | 1 |
| Duan, JA | 1 |
| Bruno, JL | 1 |
| Hosseini, SH | 1 |
| Lightbody, AA | 1 |
| Manchanda, MK | 1 |
| Reiss, AL | 1 |
| Harel, BT | 1 |
| Pietrzak, RH | 2 |
| Snyder, PJ | 2 |
| Maruff, P | 2 |
| Tan, ZH | 1 |
| Lan, HC | 1 |
| Yang, Q | 2 |
| Chen, J | 1 |
| Mao, SP | 1 |
| Zha, YF | 1 |
| Xiao, SJ | 1 |
| Rojas, G | 1 |
| Demey, I | 1 |
| Arizaga, RL | 1 |
| Sabbagh, M | 1 |
| Cummings, J | 3 |
| Christensen, D | 1 |
| Doody, R | 3 |
| Farlow, M | 1 |
| Liu, L | 1 |
| Mackell, J | 3 |
| Fain, R | 1 |
| Kadowaki Horita, T | 1 |
| Kobayashi, M | 1 |
| Mori, A | 1 |
| Jenner, P | 1 |
| Kanda, T | 1 |
| Easton, A | 1 |
| Sankaranarayanan, S | 1 |
| Tanghe, A | 1 |
| Terwel, D | 1 |
| Lin, AX | 1 |
| Hoque, N | 1 |
| Bourin, C | 1 |
| Gu, H | 1 |
| Ahlijanian, M | 1 |
| Bristow, L | 1 |
| Schmitt, FA | 1 |
| Saxton, J | 1 |
| Ferris, SH | 2 |
| Karvat, G | 1 |
| Kimchi, T | 1 |
| Davis, J | 1 |
| Ahlberg, FM | 1 |
| Berk, M | 1 |
| Ashley, DM | 1 |
| Khasraw, M | 1 |
| Omori, C | 1 |
| Kaneko, M | 1 |
| Nakajima, E | 1 |
| Akatsu, H | 1 |
| Waragai, M | 1 |
| Maeda, M | 1 |
| Morishima-Kawashima, M | 1 |
| Saito, Y | 1 |
| Nakaya, T | 1 |
| Taru, H | 1 |
| Yamamoto, T | 1 |
| Asada, T | 1 |
| Hata, S | 1 |
| Suzuki, T | 1 |
| Pelton, GH | 2 |
| Andrews, H | 1 |
| Roose, SP | 2 |
| Marcus, SM | 1 |
| D'Antonio, K | 1 |
| Husn, H | 2 |
| Petrella, JR | 2 |
| Zannas, AS | 1 |
| Doraiswamy, PM | 5 |
| Devanand, DP | 2 |
| Igeta, H | 1 |
| Suzuki, Y | 1 |
| Tajiri, M | 1 |
| Someya, T | 1 |
| Karamihalev, S | 1 |
| Prickaerts, J | 1 |
| van Goethem, NP | 1 |
| Borghgraef, C | 1 |
| Libert, Y | 1 |
| Etienne, AM | 1 |
| Delvaux, N | 1 |
| Reynaert, C | 1 |
| Razavi, D | 1 |
| Yu, D | 1 |
| Tao, BB | 1 |
| Yang, YY | 1 |
| Du, LS | 1 |
| Yang, SS | 1 |
| He, XJ | 1 |
| Zhu, YW | 1 |
| Yan, JK | 1 |
| Wilkinson, D | 4 |
| Windfeld, K | 1 |
| Colding-Jørgensen, E | 1 |
| Sadhu, A | 1 |
| Upadhyay, P | 1 |
| Agrawal, A | 1 |
| Ilango, K | 1 |
| Karmakar, D | 1 |
| Singh, GP | 1 |
| Dubey, GP | 1 |
| Day, J | 1 |
| Zienius, K | 1 |
| Gehring, K | 1 |
| Grosshans, D | 1 |
| Taphoorn, M | 1 |
| Grant, R | 1 |
| Li, J | 1 |
| Brown, PD | 1 |
| Safar, MM | 1 |
| Arab, HH | 1 |
| Rizk, SM | 1 |
| El-Maraghy, SA | 1 |
| Rapp, SR | 3 |
| Case, LD | 2 |
| Peiffer, A | 1 |
| Naughton, MM | 1 |
| Chan, MD | 1 |
| Stieber, VW | 1 |
| Moore, DF | 1 |
| Falchuk, SC | 1 |
| Piephoff, JV | 1 |
| Edenfield, WJ | 1 |
| Giguere, JK | 1 |
| Loghin, ME | 1 |
| Shaw, EG | 4 |
| Kudoh, C | 1 |
| Arita, R | 1 |
| Honda, M | 1 |
| Kishi, T | 1 |
| Komatsu, Y | 1 |
| Asou, H | 1 |
| Mimura, M | 1 |
| Inoue, J | 1 |
| Hoshino, R | 1 |
| Nojima, H | 1 |
| Ishida, W | 1 |
| Okamoto, N | 1 |
| Tagawa, R | 1 |
| Hashimoto, H | 1 |
| Nakanishi, A | 1 |
| Kawarada, Y | 1 |
| Muramatsu, T | 1 |
| Matsuda, Y | 1 |
| Kataoka, K | 1 |
| Shimada, A | 1 |
| Uchida, K | 1 |
| Yoshida, A | 1 |
| Higashiyama, S | 1 |
| Kawabe, J | 1 |
| Kai, T | 1 |
| Shiomi, S | 1 |
| Mori, H | 1 |
| Inoue, K | 2 |
| Ghumatkar, PJ | 1 |
| Patil, SP | 1 |
| Jain, PD | 1 |
| Tambe, RM | 1 |
| Sathaye, S | 1 |
| Lawrence, JA | 1 |
| Griffin, L | 1 |
| Balcueva, EP | 1 |
| Groteluschen, DL | 1 |
| Samuel, TA | 1 |
| Lesser, GJ | 1 |
| Naughton, MJ | 2 |
| Kuzmickienė, J | 1 |
| Kaubrys, G | 1 |
| Livingstone, N | 1 |
| Hanratty, J | 1 |
| McShane, R | 2 |
| Macdonald, G | 1 |
| Lopes, JB | 1 |
| de Oliveira, J | 1 |
| Engel, DF | 1 |
| de Paula, GC | 1 |
| Moreira, EL | 1 |
| de Bem, AF | 1 |
| Misik, J | 1 |
| Korabecny, J | 1 |
| Nepovimova, E | 1 |
| Kracmarova, A | 1 |
| Kassa, J | 1 |
| Correa, DD | 1 |
| Kryza-Lacombe, M | 1 |
| Baser, RE | 1 |
| Beal, K | 1 |
| DeAngelis, LM | 1 |
| Huang, L | 1 |
| Lin, J | 1 |
| Xiang, S | 1 |
| Zhao, K | 1 |
| Yu, J | 1 |
| Zheng, J | 2 |
| Xu, D | 1 |
| Mak, S | 1 |
| Hu, S | 1 |
| Nirasha, S | 1 |
| Wang, C | 1 |
| Chen, X | 2 |
| Xu, S | 1 |
| Wei, X | 1 |
| Zhou, D | 1 |
| Zhou, W | 1 |
| Cui, W | 1 |
| Han, Y | 1 |
| Hu, Z | 1 |
| Wang, Q | 2 |
| Gawel, K | 1 |
| Labuz, K | 1 |
| Gibula-Bruzda, E | 1 |
| Jenda, M | 1 |
| Marszalek-Grabska, M | 1 |
| Filarowska, J | 1 |
| Silberring, J | 1 |
| Kotlinska, JH | 1 |
| Mellios, G | 1 |
| Lim, I | 1 |
| Joung, HY | 1 |
| Yu, AR | 1 |
| Shim, I | 1 |
| Kim, JS | 1 |
| Gault, LM | 1 |
| Lenz, RA | 2 |
| Ritchie, CW | 1 |
| Meier, A | 1 |
| Othman, AA | 1 |
| Tang, Q | 1 |
| Berry, S | 1 |
| Pritchett, Y | 1 |
| Robieson, WZ | 1 |
| Perez-Lloret, S | 1 |
| Peralta, MC | 1 |
| Barrantes, FJ | 1 |
| Meguro, M | 1 |
| Kasai, M | 1 |
| Akanuma, K | 1 |
| Ishii, H | 1 |
| Yamaguchi, S | 1 |
| Meguro, K | 1 |
| Sugimoto, H | 1 |
| Whyte, EM | 1 |
| Lenze, EJ | 1 |
| Butters, M | 1 |
| Skidmore, E | 1 |
| Koenig, K | 1 |
| Dew, MA | 1 |
| Penrod, L | 1 |
| Mulsant, BH | 2 |
| Pollock, BG | 1 |
| Cabacungan, L | 1 |
| Reynolds, CF | 2 |
| Munin, MC | 1 |
| Yusim, A | 1 |
| Anbarasan, D | 1 |
| Bernstein, C | 1 |
| Boksay, I | 1 |
| Dulchin, M | 1 |
| Lindenmayer, JP | 1 |
| Saavedra-Velez, C | 1 |
| Shapiro, M | 1 |
| Sadock, B | 1 |
| Wattmo, C | 1 |
| Hansson, O | 1 |
| Wallin, AK | 1 |
| Londos, E | 1 |
| Minthon, L | 1 |
| Tosto, G | 1 |
| Talarico, G | 1 |
| Lenzi, GL | 1 |
| Bruno, G | 1 |
| van Straaten, EC | 1 |
| Harvey, D | 2 |
| Scheltens, P | 2 |
| Barkhof, F | 1 |
| Petersen, RC | 8 |
| Thal, LJ | 5 |
| Jack, CR | 3 |
| DeCarli, C | 2 |
| Prince, SE | 1 |
| Krishnan, S | 1 |
| Kelley, L | 1 |
| Irizarry, MC | 1 |
| Raman, R | 2 |
| Schwarzschild, MA | 1 |
| Becerra, LM | 1 |
| Thomas, RG | 2 |
| Peterson, RC | 1 |
| Ascherio, A | 1 |
| Aisen, PS | 2 |
| Knopman, DS | 2 |
| Doody, RS | 5 |
| Salloway, S | 5 |
| Goldman, R | 4 |
| Watkins, WE | 1 |
| Xu, Y | 3 |
| Murthy, AK | 2 |
| Rao, NP | 1 |
| Palaniyappan, P | 1 |
| Chandur, J | 1 |
| Venkatasubramanian, G | 1 |
| Gangadhar, BN | 1 |
| Cutuli, D | 1 |
| Foti, F | 1 |
| Mandolesi, L | 1 |
| De Bartolo, P | 1 |
| Gelfo, F | 1 |
| Federico, F | 1 |
| Petrosini, L | 1 |
| Kunitachi, S | 1 |
| Fujita, Y | 1 |
| Ishima, T | 1 |
| Kohno, M | 1 |
| Horio, M | 1 |
| Tanibuchi, Y | 1 |
| Shirayama, Y | 1 |
| Iyo, M | 1 |
| Hashimoto, K | 1 |
| Chung, YC | 1 |
| Lee, CR | 1 |
| Park, TW | 1 |
| Yang, KH | 1 |
| Kim, KW | 1 |
| Lu, PH | 1 |
| Edland, SD | 1 |
| Teng, E | 1 |
| Tingus, K | 1 |
| Cummings, JL | 3 |
| Montero-Odasso, M | 1 |
| Wells, JL | 1 |
| Borrie, MJ | 1 |
| Speechley, M | 1 |
| Parlayan, E | 1 |
| Yulug, B | 1 |
| Bakar, M | 1 |
| Gumustas, O | 1 |
| Crane, PK | 1 |
| Katona, C | 1 |
| Hanyu, H | 1 |
| Sato, T | 1 |
| Hirao, K | 1 |
| Kanetaka, H | 1 |
| Iwamoto, T | 1 |
| Koizumi, K | 1 |
| Ferris, S | 3 |
| Gao, J | 1 |
| Chonpathompikunlert, P | 1 |
| Wattanathorn, J | 1 |
| Muchimapura, S | 1 |
| Wang, L | 2 |
| Harms, MP | 1 |
| Staggs, JM | 1 |
| Xiong, C | 1 |
| Morris, JC | 1 |
| Csernansky, JG | 1 |
| Galvin, JE | 1 |
| Panza, F | 1 |
| Frisardi, V | 1 |
| Capurso, C | 1 |
| D'Introno, A | 1 |
| Colacicco, AM | 1 |
| Chiloiro, R | 1 |
| Dellegrazie, F | 1 |
| Di Palo, A | 1 |
| Capurso, A | 1 |
| Solfrizzi, V | 1 |
| Suda, S | 1 |
| Sugihara, G | 1 |
| Suyama, R | 1 |
| Mori, N | 1 |
| Takei, N | 1 |
| Jones, R | 2 |
| Lopez, O | 1 |
| Gauthier, S | 4 |
| Waldemar, G | 3 |
| Zhang, R | 4 |
| Richardson, S | 5 |
| Whitehair, DC | 1 |
| Sherzai, A | 1 |
| Emond, J | 1 |
| Fleisher, AS | 2 |
| Lopez, OL | 1 |
| Schwam, E | 1 |
| Kishnani, PS | 1 |
| Heller, JH | 1 |
| Spiridigliozzi, GA | 1 |
| Lott, I | 1 |
| Escobar, L | 1 |
| McRae, T | 2 |
| Frölich, L | 1 |
| Ashwood, T | 1 |
| Nilsson, J | 1 |
| Eckerwall, G | 1 |
| Piau, A | 1 |
| Caillaud, C | 1 |
| Voisin, T | 1 |
| Vellas, B | 1 |
| Getsios, D | 1 |
| Blume, S | 1 |
| Ishak, KJ | 1 |
| Maclaine, G | 1 |
| Hernández, L | 1 |
| Kondoh, T | 2 |
| Kanno, A | 1 |
| Itoh, H | 1 |
| Nakashima, M | 2 |
| Honda, R | 1 |
| Kojima, M | 1 |
| Noguchi, M | 1 |
| Nakane, H | 1 |
| Nozaki, H | 1 |
| Sasaki, H | 2 |
| Nagai, T | 2 |
| Kosaki, R | 1 |
| Kakee, N | 1 |
| Okuyama, T | 1 |
| Fukuda, M | 1 |
| Ikeda, M | 1 |
| Shibata, Y | 1 |
| Moriuchi, H | 2 |
| Yamada, M | 1 |
| Hayashida, M | 1 |
| Zhao, Q | 1 |
| Shibahara, N | 1 |
| Tanaka, K | 1 |
| Miyata, T | 1 |
| Matsumoto, K | 1 |
| Chang, WH | 1 |
| Park, YH | 1 |
| Ohn, SH | 1 |
| Park, CH | 1 |
| Lee, PK | 1 |
| Kim, YH | 2 |
| Duan, W | 1 |
| Chun-Qing, Z | 1 |
| Gui, L | 1 |
| Huang, HQ | 1 |
| Chen, KN | 1 |
| Goveas, JS | 2 |
| Xie, C | 2 |
| Ward, BD | 2 |
| Wu, Z | 1 |
| Li, W | 2 |
| Franczak, M | 1 |
| Jones, JL | 2 |
| Antuono, PG | 2 |
| Li, SJ | 2 |
| Winocur, G | 1 |
| Binns, MA | 1 |
| Tannock, I | 1 |
| Yadav, V | 1 |
| Bourdette, DN | 1 |
| Furukawa-Hibi, Y | 1 |
| Alkam, T | 1 |
| Nitta, A | 1 |
| Matsuyama, A | 1 |
| Mizoguchi, H | 1 |
| Suzuki, K | 1 |
| Moussaoui, S | 1 |
| Yu, QS | 1 |
| Greig, NH | 1 |
| Yamada, K | 1 |
| Baker, JD | 1 |
| Locke, C | 1 |
| Rueter, LE | 1 |
| Mohler, EG | 1 |
| Wesnes, K | 1 |
| Abi-Saab, W | 1 |
| Saltarelli, MD | 1 |
| Song, IU | 1 |
| Cho, HJ | 1 |
| Kim, YD | 1 |
| Chung, SW | 1 |
| Rosenzweig, I | 1 |
| Ramachandra, P | 1 |
| Freer, J | 1 |
| Wong, M | 1 |
| Pieters, T | 1 |
| Ishiuchi, S | 1 |
| Strober, LB | 1 |
| Christodoulou, C | 1 |
| Benedict, RH | 1 |
| Westervelt, HJ | 1 |
| Melville, P | 1 |
| Scherl, WF | 1 |
| Weinstock-Guttman, B | 1 |
| Rizvi, S | 1 |
| Goodman, AD | 1 |
| Krupp, LB | 1 |
| O'Carroll, CB | 1 |
| Woodruff, BK | 1 |
| Locke, DE | 1 |
| Hoffman-Snyder, CR | 1 |
| Wellik, KE | 1 |
| Thaera, GM | 1 |
| Demaerschalk, BM | 1 |
| Wingerchuk, DM | 1 |
| Castellino, SM | 1 |
| Tooze, JA | 1 |
| Flowers, L | 1 |
| Hill, DF | 1 |
| McMullen, KP | 1 |
| Parsons, SK | 1 |
| Min, D | 1 |
| Mao, X | 1 |
| Wu, K | 1 |
| Cao, Y | 1 |
| Guo, F | 1 |
| Zhu, S | 1 |
| Xie, N | 1 |
| Chen, T | 1 |
| Shaw, C | 1 |
| Cai, J | 1 |
| Chen, G | 1 |
| Franczak, MB | 1 |
| McDermott, CL | 1 |
| Gray, SL | 1 |
| Rolinski, M | 1 |
| Fox, C | 1 |
| Maidment, I | 1 |
| Cannon, CE | 1 |
| Puri, V | 1 |
| Vivian, JA | 1 |
| Egbertson, MS | 1 |
| Eddins, D | 1 |
| Uslaner, JM | 1 |
| Andersen, F | 1 |
| Viitanen, M | 1 |
| Halvorsen, DS | 1 |
| Straume, B | 1 |
| Wilsgaard, T | 1 |
| Engstad, TA | 1 |
| Wergin, R | 1 |
| Modrykamien, A | 1 |
| Thakurathi, N | 1 |
| Vincenzi, B | 1 |
| Henderson, DC | 2 |
| Saine, K | 1 |
| Cullum, CM | 1 |
| Martin-Cook, K | 1 |
| Hynan, L | 1 |
| Svetlik, DA | 1 |
| Weiner, MF | 1 |
| Graham, JE | 1 |
| Fay, S | 2 |
| Buchanan, RW | 2 |
| Summerfelt, A | 1 |
| Tek, C | 1 |
| Gold, J | 1 |
| Bourgeois, JA | 2 |
| Bahadur, N | 1 |
| Minjares, S | 1 |
| Falk, WE | 1 |
| Daly, EJ | 1 |
| Tsai, GE | 1 |
| Gunther, J | 1 |
| Brown, P | 1 |
| Allain, H | 2 |
| Bentue-Ferrer, D | 2 |
| Belliard, S | 1 |
| Reymann, JM | 1 |
| Djemaï, M | 1 |
| Merienne, M | 1 |
| Bowler, JV | 1 |
| Werber, EA | 1 |
| Gandelman-Marton, R | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| Margallo-Lana, ML | 1 |
| Ballard, C | 1 |
| Morris, C | 1 |
| Kay, D | 1 |
| Tyrer, S | 1 |
| Moore, B | 1 |
| Harvey, R | 1 |
| Nahas, Z | 2 |
| George, MS | 2 |
| Horner, MD | 2 |
| Markowitz, JS | 2 |
| Li, X | 1 |
| Lorberbaum, JP | 1 |
| Owens, SD | 2 |
| McGurk, S | 2 |
| DeVane, L | 1 |
| Risch, SC | 2 |
| Kurita, A | 1 |
| Ochiai, Y | 1 |
| Kono, Y | 1 |
| Suzuki, M | 1 |
| Ihl, R | 1 |
| Johnson, N | 1 |
| Fahey, C | 1 |
| Chicoine, B | 1 |
| Chong, G | 1 |
| Gitelman, D | 1 |
| Román, GC | 1 |
| Rogers, SJ | 1 |
| Tuğal, O | 1 |
| Yazici, KM | 1 |
| Anil Yağcioğlu, AE | 1 |
| Göğüş, A | 1 |
| Malouf, R | 1 |
| Birks, J | 3 |
| Erkinjuntti, T | 1 |
| Román, G | 1 |
| Feldman, H | 1 |
| Ueki, A | 1 |
| Shinjo, H | 1 |
| Shimode, H | 1 |
| Nakajima, T | 1 |
| Morita, Y | 1 |
| Kim, KY | 1 |
| Ke, V | 1 |
| Adkins, LM | 1 |
| Saykin, AJ | 1 |
| Wishart, HA | 1 |
| Rabin, LA | 1 |
| Flashman, LA | 1 |
| McHugh, TL | 1 |
| Mamourian, AC | 1 |
| Santulli, RB | 1 |
| Kaufer, DI | 2 |
| Walker, W | 1 |
| Seel, R | 1 |
| Gibellato, M | 1 |
| Lew, H | 1 |
| Cornis-Pop, M | 1 |
| Jena, T | 1 |
| Silver, T | 1 |
| Mossello, E | 1 |
| Tonon, E | 1 |
| Caleri, V | 1 |
| Tilli, S | 1 |
| Cantini, C | 1 |
| Cavallini, MC | 1 |
| Bencini, F | 1 |
| Mecacci, R | 1 |
| Marini, M | 2 |
| Bardelli, F | 1 |
| Sarcone, E | 1 |
| Razzi, E | 1 |
| Biagini, CA | 1 |
| Masotti, G | 1 |
| Buccafusco, JJ | 1 |
| Terry, AV | 1 |
| Kluger, A | 1 |
| Griesing, T | 1 |
| Kumar, D | 1 |
| Tsukada, H | 1 |
| Jatoi, A | 1 |
| Kahanic, SP | 1 |
| Frytak, S | 1 |
| Schaefer, P | 1 |
| Foote, RL | 1 |
| Sloan, J | 1 |
| Akwa, Y | 1 |
| Rao, SM | 1 |
| Tenovuo, O | 1 |
| Simard, M | 1 |
| van Reekum, R | 1 |
| Stern, RA | 1 |
| Davis, JD | 1 |
| Rogers, BL | 1 |
| Smith, KE | 1 |
| Harrington, CJ | 1 |
| Ott, BR | 1 |
| Jackson, IM | 1 |
| Prange, AJ | 1 |
| Olazarán, J | 1 |
| Muñiz, R | 1 |
| Reisberg, B | 1 |
| Peña-Casanova, J | 1 |
| del Ser, T | 1 |
| Cruz-Jentoft, AJ | 1 |
| Serrano, P | 1 |
| Navarro, E | 1 |
| García de la Rocha, ML | 1 |
| Frank, A | 1 |
| Galiano, M | 1 |
| Fernández-Bullido, Y | 1 |
| Serra, JA | 1 |
| González-Salvador, MT | 1 |
| Sevilla, C | 1 |
| Wang, LN | 1 |
| Wang, W | 1 |
| Zhang, XH | 1 |
| Ma, L | 1 |
| Yin, H | 1 |
| Li, DJ | 1 |
| Bergman, J | 1 |
| Dwolatzky, T | 1 |
| Brettholz, I | 1 |
| Lerner, V | 1 |
| Harry, RD | 1 |
| Zakzanis, KK | 1 |
| Amamoto, N | 1 |
| Doi, T | 1 |
| Hamada, H | 1 |
| Ogawa, Y | 1 |
| Aikawa, K | 1 |
| Tanaka, T | 1 |
| Aoki, M | 1 |
| Harada, J | 1 |
| Bohnen, NI | 1 |
| Hendrickson, R | 1 |
| Ivanco, LS | 1 |
| Lopresti, BJ | 1 |
| Koeppe, RA | 1 |
| Meltzer, CC | 1 |
| Constantine, G | 1 |
| Davis, JG | 1 |
| Mathis, CA | 1 |
| Dekosky, ST | 1 |
| Moore, RY | 1 |
| Freudenreich, O | 1 |
| Herz, L | 1 |
| Deckersbach, T | 1 |
| Evins, AE | 1 |
| Cather, C | 1 |
| Goff, DC | 1 |
| Grundman, M | 3 |
| Bennett, D | 1 |
| Galasko, D | 2 |
| Jin, S | 3 |
| Kaye, J | 1 |
| Levey, A | 1 |
| Pfeiffer, E | 1 |
| Sano, M | 1 |
| van Dyck, CH | 1 |
| Blacker, D | 2 |
| Fukui, T | 1 |
| Taguchi, S | 1 |
| Geldmacher, DS | 1 |
| Raschetti, R | 1 |
| Maggini, M | 1 |
| Sorrentino, GC | 1 |
| Martini, N | 1 |
| Caffari, B | 1 |
| Vanacore, N | 2 |
| Logan, A | 1 |
| Khateb, A | 1 |
| Ammann, J | 1 |
| Annoni, JM | 1 |
| Diserens, K | 1 |
| Marder, K | 1 |
| Kirshner, HS | 1 |
| Kircher, TT | 1 |
| Erb, M | 1 |
| Grodd, W | 1 |
| Leube, DT | 1 |
| Jelic, V | 1 |
| Kivipelto, M | 1 |
| Winblad, B | 2 |
| Niwa, H | 1 |
| Koumoto, C | 1 |
| Shiga, T | 1 |
| Takeuchi, J | 1 |
| Mishima, S | 1 |
| Segawa, T | 1 |
| Atsumi, T | 1 |
| Shimizu, C | 1 |
| Koike, T | 1 |
| Yoshioka, N | 1 |
| Wilens, TE | 1 |
| Waxmonsky, J | 1 |
| Scott, M | 1 |
| Swezey, A | 1 |
| Kwon, A | 1 |
| Spencer, TJ | 1 |
| Biederman, J | 1 |
| Kouta, Y | 1 |
| Sakurai, T | 1 |
| Yokono, K | 1 |
| Kitabayashi, Y | 1 |
| Ueda, H | 1 |
| Tsuchida, H | 1 |
| Yamashita, T | 1 |
| Narumoto, J | 1 |
| Fukui, K | 1 |
| Mazeh, D | 1 |
| Zemishlani, H | 1 |
| Barak, Y | 1 |
| Mirecki, I | 1 |
| Paleacu, D | 1 |
| Wheeler, SD | 1 |
| Wimo, A | 1 |
| Engedal, K | 1 |
| Soininen, H | 1 |
| Verhey, F | 1 |
| Wetterholm, AL | 1 |
| Haglund, A | 1 |
| Ownby, RL | 1 |
| Bennett, BM | 1 |
| Reynolds, JN | 1 |
| Prusky, GT | 1 |
| Douglas, RM | 1 |
| Sutherland, RJ | 1 |
| Thatcher, GR | 1 |
| Rosdhal, R | 1 |
| D'Agostino, RB | 1 |
| Lovato, J | 1 |
| Robbins, ME | 1 |
| Aupperle, PM | 1 |
| Stiles, MM | 1 |
| Martin, S | 1 |
| Persons, RK | 1 |
| Asp, E | 1 |
| Cloutier, F | 1 |
| Cook, C | 1 |
| Robertson, ML | 1 |
| Fisk, J | 1 |
| Dei, DW | 1 |
| McCaffrey, P | 1 |
| Magnotta, VA | 1 |
| Duff, K | 1 |
| Boles Ponto, LL | 1 |
| Schultz, SK | 2 |
| Sugden, SG | 1 |
| Kile, SJ | 1 |
| Farrimond, DD | 1 |
| Hilty, DM | 1 |
| Pérez, M | 1 |
| Tůma, I | 1 |
| Pytela, O | 1 |
| Kadlecová, E | 1 |
| Zemanová, M | 1 |
| Lenderová, Z | 1 |
| Sakakibara, R | 1 |
| Uchiyama, T | 1 |
| Hattori, T | 1 |
| Lindner, MD | 1 |
| Hogan, JB | 1 |
| Hodges, DB | 1 |
| Orie, AF | 1 |
| Chen, P | 1 |
| Corsa, JA | 1 |
| Leet, JE | 1 |
| Gillman, KW | 1 |
| Rose, GM | 1 |
| Jones, KM | 1 |
| Gribkoff, VK | 1 |
| Cubo, E | 1 |
| Shannon, KM | 1 |
| Tracy, D | 1 |
| Jaglin, JA | 1 |
| Bernard, BA | 1 |
| Wuu, J | 1 |
| Leurgans, SE | 1 |
| Lee, BJ | 1 |
| Lee, JG | 1 |
| Rozzini, L | 1 |
| Costardi, D | 1 |
| Chilovi, BV | 1 |
| Franzoni, S | 1 |
| Trabucchi, M | 2 |
| Padovani, A | 1 |
| Ferreri, F | 1 |
| Agbokou, C | 1 |
| Zhang, P | 1 |
| Chen, L | 1 |
| Gu, W | 1 |
| Xu, Z | 1 |
| Gao, Y | 1 |
| Li, Y | 1 |
| Frisoni, GB | 1 |
| Clark, CM | 1 |
| Sowell, BB | 1 |
| Taylor, C | 1 |
| Gamst, AC | 1 |
| Kondro, W | 1 |
| McLay, RN | 1 |
| Ho, J | 1 |
| Campanozzi, MD | 1 |
| Casali, E | 1 |
| Neviani, F | 1 |
| Martini, E | 1 |
| Neri, M | 1 |
| Small, BJ | 1 |
| Gagnon, E | 1 |
| Robinson, B | 1 |
| Gamst, A | 1 |
| Ward, CP | 1 |
| Sencakova, D | 1 |
| Hamberger, MJ | 1 |
| Palmese, CA | 1 |
| Scarmeas, N | 2 |
| Weintraub, D | 1 |
| Choi, H | 1 |
| Hirsch, LJ | 1 |
| Saumier, D | 1 |
| Murtha, S | 1 |
| Bergman, H | 1 |
| Phillips, N | 1 |
| Whitehead, V | 1 |
| Chertkow, H | 1 |
| Babyak, MA | 1 |
| Hennig, T | 1 |
| Trivedi, R | 1 |
| White, WD | 1 |
| Mathew, JP | 1 |
| Newman, MF | 1 |
| Blumenthal, JA | 1 |
| Correia, S | 1 |
| Keefe, RS | 1 |
| Malhotra, AK | 1 |
| Meltzer, HY | 1 |
| Kane, JM | 1 |
| Murthy, A | 1 |
| Sovel, M | 1 |
| Li, C | 1 |
| Black, SE | 1 |
| Jambor, KM | 1 |
| Perdomo, CA | 1 |
| Kohler, CG | 1 |
| Martin, EA | 1 |
| Kujawski, E | 1 |
| Bilker, W | 1 |
| Gur, RE | 1 |
| Gur, RC | 1 |
| Albert, MS | 1 |
| Kelly, T | 1 |
| Lee, JH | 1 |
| Park, SY | 1 |
| Shin, YW | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Voss, B | 1 |
| Thienel, R | 1 |
| Kircher, T | 1 |
| Hager, K | 1 |
| Kenklies, M | 1 |
| McAfoose, J | 1 |
| Engel, J | 1 |
| Münch, G | 1 |
| Arai, T | 1 |
| Harper, OL | 1 |
| Tabert, MH | 1 |
| Sackeim, HA | 1 |
| Gildengers, AG | 1 |
| Butters, MA | 1 |
| Chisholm, D | 1 |
| Nyenhuis, DL | 1 |
| Gorelick, PB | 1 |
| Devi, G | 1 |
| Massimi, S | 1 |
| Schultz, S | 1 |
| Khosrowshahi, L | 1 |
| Laakso, UK | 1 |
| Rueda, N | 1 |
| Flórez, J | 1 |
| Martínez-Cué, C | 1 |
| Lyle, S | 1 |
| Grizzell, M | 1 |
| Willmott, S | 1 |
| Benbow, S | 1 |
| Clark, M | 1 |
| Jolley, D | 1 |
| Ames, D | 1 |
| Kaduszkiewicz, H | 1 |
| van den Bussche, H | 1 |
| Zimmermann, T | 1 |
| Ashby, D | 1 |
| Dichgans, M | 1 |
| Markus, HS | 1 |
| Verkkoniemi, A | 1 |
| Moline, M | 1 |
| Posner, H | 1 |
| Chabriat, HS | 1 |
| Foster, M | 1 |
| Spiegel, DR | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Schneider, LS | 2 |
| Boothby, H | 1 |
| Zaidi, SM | 1 |
| Seth, V | 1 |
| Khalaf, S | 1 |
| Jameel, H | 1 |
| Mahomed, S | 1 |
| Stewart, A | 1 |
| Phillips, R | 1 |
| Dempsey, G | 1 |
| Peskind, ER | 1 |
| Magnuson, TM | 1 |
| Keller, BK | 1 |
| Burke, WJ | 2 |
| Karlawish, JH | 1 |
| Whitehouse, PJ | 1 |
| Lacomblez, L | 1 |
| Wengel, SP | 1 |
| Roccaforte, WH | 1 |
| Greene, YM | 2 |
| Noviasky, J | 2 |
| Tariot, PN | 2 |
| Whitlock, JA | 1 |
| McLendon, BM | 1 |
| Mega, MS | 1 |
| Masterman, DM | 1 |
| O'Connor, SM | 1 |
| Barclay, TR | 1 |
| Birks J, S | 1 |
| Melzer, D | 1 |
| Wishart, H | 1 |
| Cox, C | 1 |
| Holt, CJ | 1 |
| Schwid, S | 1 |
| Whelan, FJ | 1 |
| Walker, MS | 1 |
| Samuel, W | 1 |
| Caligiuri, M | 1 |
| Lacro, J | 1 |
| McClure, FS | 1 |
| Warren, K | 1 |
| Jeste, DV | 1 |
| Yorston, GA | 1 |
| Gray, R | 1 |
| Fabbrini, G | 1 |
| Barbanti, P | 1 |
| Bonifati, V | 1 |
| Colosimo, C | 1 |
| Gasparini, M | 1 |
| Meco, G | 1 |
| Molloy, M | 1 |
| Gilliard, C | 1 |
| Christie, S | 1 |
| DeVane, CL | 1 |
| Mintzer, J | 1 |
| Rice, DP | 1 |
| Fillit, HM | 1 |
| Max, W | 1 |
| Lloyd, JR | 1 |
| Duttagupta, S | 1 |
| Friedman, JI | 1 |
| Adler, DN | 1 |
| Howanitz, E | 1 |
| Harvey, PD | 1 |
| Brenner, G | 1 |
| Temporini, H | 1 |
| White, L | 1 |
| Parrella, M | 1 |
| Davis, KL | 1 |
| Aarsland, D | 1 |
| Laake, K | 1 |
| Larsen, JP | 1 |
| Janvin, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donep[NCT01712074] | Phase 2 | 186 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria were met. The termination was not due to safety concerns.) | ||
| Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-[NCT01129596] | 10,238 participants (Actual) | Observational | 2010-06-10 | Completed | |||
| Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease[NCT00478205] | Phase 3 | 1,467 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression[NCT01658228] | Phase 4 | 86 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil[NCT01019421] | Phase 2 | 278 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study: an Ambispective, Multicentre, Open Cohort Study[NCT03401619] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2017-09-21 | Active, not recruiting | |||
| UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions[NCT04343157] | Phase 2 | 60 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| A Randomized Placebo-controlled Trial of Ashwagandha (Withania Somnifera) for Cognitive Dysfunction Associated With Cancer Chemotherapy.[NCT04092647] | Phase 2 | 80 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985[NCT01676935] | Phase 2 | 349 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.) | ||
| A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease[NCT01527916] | Phase 2 | 438 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Donepezil to Promote Functional Recovery Post-stroke[NCT00868010] | Phase 3 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly[NCT00227994] | Phase 4 | 40 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Can Cognitive Enhancers Reduce the Risk of Falls in Older People With Mild Cognitive Impairment? A Randomized Controled Trial[NCT00934531] | 60 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's[NCT02987842] | 30 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | |||
| Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis[NCT02988401] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| Phase 4 Study of Cognitive Therapy and Donepezil in Alzheimers Disease.[NCT00443014] | Phase 4 | 187 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.[NCT01772095] | 389 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)[NCT00006349] | Phase 3 | 9 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease[NCT02521558] | 30 participants (Actual) | Interventional | 2015-09-30 | Terminated (stopped due to Enrollment was halted early because of low adherence to the intervention.) | |||
| A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)[NCT00567060] | 676 participants (Actual) | Interventional | 2000-05-31 | Completed | |||
| Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases[NCT00070161] | Phase 2 | 68 participants (Actual) | Interventional | 2001-07-01 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)[NCT00000173] | Phase 3 | 0 participants | Interventional | 1999-03-31 | Completed | ||
| A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)[NCT01429623] | Phase 2 | 210 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery[NCT01186289] | 0 participants (Actual) | Interventional | 2010-10-31 | Withdrawn (stopped due to Principal Investigator decided not to pursue enrollment due to changes in standard of care.) | |||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study[NCT04249869] | Phase 1/Phase 2 | 28 participants (Anticipated) | Interventional | 2020-02-01 | Not yet recruiting | ||
| Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial[NCT02781220] | 69 participants (Actual) | Observational | 2016-07-31 | Active, not recruiting | |||
| Implications for Management of PET Amyloid Classification Technology[NCT02778971] | 41 participants (Actual) | Observational | 2016-06-30 | Completed | |||
| An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment[NCT00103948] | Phase 2 | 165 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia[NCT02415062] | Phase 2 | 150 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ADAS-cog13 (13-item ADAS cog) is a psychometric instrument that evaluates word recall, ability to follow commands, constructional praxis, naming, ideational praxis, orientation, word recognition, memory, comprehension of spoken language, word-finding, and language ability, with a measure of delayed word recall and concentration/ distractibility. The total score of the 13-item scale ranges from 0 to 85, with an increase in score indicating cognitive worsening. (NCT01712074)
Timeframe: Baseline and Week 16
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| PF-05212377 30 mg | 0.111 |
| Placebo | -0.584 |
The NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, as well as appetite/eating. The NPI total score (for 12 behavioral domains) is calculated as the product of frequency and severity for each domain, and ranges from 0 to 144. An increase in score indicates a worsening of symptoms. (NCT01712074)
Timeframe: Baseline and Week 16
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| PF-05212377 30 mg | -3.990 |
| Placebo | -6.184 |
Proportion of participants with TEAEs leading to discontinuation over the 12-week double blind treatment period and washout. Adverse events (AEs) occurring following start of treatment or increasing in severity were counted as treatment emergent (NCT01712074)
Timeframe: Week 4 to Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| PF-05212377 30 mg | 3.3 |
| Placebo | 0 |
"Proportion (%) of participants with laboratory abnormalities (without regard to baseline abnormalities) of potential clinical concern over the 12-week double blind treatment period.~The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, uric acid, albumin, and total protein; urinalysis (pH, glucose, protein/albumin, hemoglobin/blood, ketones/acetone, nitrites, leukocyte esterase, microscopy [if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase]); others (only at screening or needed: urine drug screen, thyroid panel, Vitamin B12, methylmalonic acid, folate and Hemoglobin A1)." (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) |
|---|---|
| PF-05212377 30 mg | 36.0 |
| Placebo | 52.0 |
The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.1 |
| Placebo | -1.3 |
The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -2.5 |
| Placebo | -1.6 |
The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | milliseconds (msec) (Mean) |
|---|---|
| PF-05212377 30 mg | -2.8 |
| Placebo | -3.6 |
The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.1 |
| Placebo | 0.1 |
The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | 0.1 |
| Placebo | -0.3 |
The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.3 |
| Placebo | -0.8 |
The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -0.2 |
| Placebo | -5.5 |
The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | 0.8 |
| Placebo | -2.2 |
The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | msec (Mean) |
|---|---|
| PF-05212377 30 mg | -3.0 |
| Placebo | -4.9 |
The BP changes from baseline at Week 6 (Visit 3) including supine systolic BP, standing systolic BP, standing systolic BP, supine diastolic BP, standing diastolic BP. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | millimeters of mercury (mm Hg) (Mean) | |||
|---|---|---|---|---|
| Supine Systolic BP | Standing Systolic BP | Supine Diastolic BP | Standing Diastolic BP | |
| PF-05212377 30 mg | -3.6 | -4.1 | -2.2 | -1.1 |
| Placebo | -3.9 | -3.0 | -1.8 | -1.0 |
The BP changes from baseline at Week 10 (Visit 4) including supine systolic BP, standing systolic BP, standing systolic BP, supine diastolic BP, standing diastolic BP. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Supine Systolic BP | Standing Systolic BP | Supine Diastolic BP | Standing Diastolic BP | |
| PF-05212377 30 mg | -3.4 | -3.8 | -2.4 | -1.2 |
| Placebo | -0.3 | 0.8 | -0.7 | 0.3 |
The BP changes from baseline at Week 16/Early Termination (Visit 5) including supine systolic BP, standing systolic BP, standing systolic BP, supine diastolic BP, standing diastolic BP. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Supine Systolic BP | Standing Systolic BP | Supine Diastolic BP | Standing Diastolic BP | |
| PF-05212377 30 mg | -1.4 | -1.0 | -2.1 | -0.8 |
| Placebo | -1.1 | -1.1 | -0.3 | 0.0 |
"Participants in each category of the Columbia Classification Algorithm of Suicide Assessment (C-CASA) mapped from the Columbia-Suicide Severity Rating Scale (C-SSRS) responses were reported.~C-CASA Event Code: <1> Completed suicide; <2> Suicide attempt; <3> Preparatory acts towards imminent suicidal behavior; <4> Suicidal Ideation; <7> Self-injurious behavior, no suicidal intent.~The suicidality assessments were performed at Screening, Week 0 (Visit 1), Week 4 (Visit 2), Week 6, (Visit 3), Week 10 (Visit 4), Week 16 (Visit 5), and Week 18 (Visit 6).~Only participants falling any category of C-CASA events were listed below." (NCT01712074)
Timeframe: From Screening to Week 18/Early Termination
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 4 (Visit 2): <4> | Week 6 (Visit 3): <4> | Week 10 (Visit 4): : <4> | Week 16/Early Termination (Visit 5): <4> | Week 4 (Visit 2): <7> | Week 6 (Visit 3): <7> | |
| PF-05212377 30 mg | 2 | 0 | 2 | 1 | 0 | 1 |
| Placebo | 1 | 1 | 0 | 0 | 1 | 0 |
| Placebo Run-in | 1 | 0 | 0 | 0 | 0 | 0 |
Proportion (%) of participants with PR Interval abnormalities meeting categorical criteria over the 12 week double blind treatment period. The PR interval is the time from the onset of the P wave to the start of the QRS complex (the combination of the Q wave, R wave and S wave, representing ventricular depolarization). Participants with post-baseline PR absolute value>=300 msec , a PR increase of >=25% (for participants with a baseline value>=200 msec), or with an increase >=50% (for participants with a baseline value<200 msec) were counted. (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Post-Baseline Maximum Absolute Value >=300 msec | Post-Baseline Maximum Increase >=25/50% | |
| PF-05212377 30 mg | 0 | 0 |
| Placebo | 4.4 | 0 |
Proportion (%) of participants with vital signs abnormalities (absolute and change from baseline) meeting categorical criteria over the 12-week double blind treatment period were counted. Vital signs data included blood pressure (BP) and pulse rate. (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absolute Supine Systolic BP<90 mmHg | Absolute Standing Systolic BP<90 mmHg | Absolute Supine Diastolic BP<50 mmHg | Absolute Standing Diastolic BP <50 mmHg | Absolute Supine Pulse Rate <40 bpm | Absolute Supine Pulse Rate >120 bpm | Absolute Standing Pulse Rate <40 bpm | Absolute Standing Pulse Rate >140 bpm | Increase in Supine Systolic BP>=30 mmHg | Increase in Standing Systolic BP>=30 mmHg | Increase in Supine Diastolic BP >=20 mmHg | Increase in Standing Diastolic BP >=20 mmHg | Decrease in Supine Systolic BP>=30 mmHg | Decrease in Standing Systolic BP>=30 mmHg | Decrease in Supine Diastolic BP >=20 mmHg | Decrease in Standing Diastolic BP >=20 mmHg | |
| PF-05212377 30 mg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.2 | 4.4 | 3.3 | 5.5 | 5.5 | 8.8 | 4.4 |
| Placebo | 1.1 | 1.1 | 2.1 | 0 | 0 | 0 | 0 | 0 | 5.3 | 3.2 | 4.3 | 5.3 | 5.3 | 5.3 | 5.3 | 6.4 |
Proportion (%) of participants with QRS Complex abnormalities meeting categorical criteria over the 12 week double blind treatment period. The QRS complex is the combination of the Q wave, R wave and S wave, representing ventricular depolarization). Participants with post-baseline QRS complex absolute value>=100 msec , a QRS complex increase of >=25% (for participants with a baseline value>=100 msec), or with an increase >=50% (for participants with a baseline value<100 msec) were counted. (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Post-Baseline Maximum Absolute Value >=200 msec | Post-Baseline Maximum Increase >=25/50% | |
| PF-05212377 30 mg | 0 | 0 |
| Placebo | 0 | 0 |
"Proportion (%) of participants with QTcF Interval abnormalities meeting categorical criteria over the 12-week double blind treatment period. The QTcF interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, which is corrected for heart rate using Fridericia's formula.~Participants with a post-baseline QTcF absolute value of 450 - <480, 480 - <500, or >=500 mec, or with a post-baseline QTcF increase of 30 - <60 or >=60 msec were counted." (NCT01712074)
Timeframe: Week 4 to Week 16
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Post-Baseline Absolute Value of 450-<480 msec | Post-Baseline Absolute Value of 480-<500 msec | Change from Baseline of 30 -<60 msec | Change from Baseline >=60 msec | |
| PF-05212377 30 mg | 15.4 | 4.4 | 6.6 | 0 |
| Placebo | 14.0 | 1.1 | 3.2 | 0 |
The pulse rate changes from baseline at Week 10 (Visit 4) including supine pulse rate, and standing pulse rate. (NCT01712074)
Timeframe: Baseline and Week 10
| Intervention | bpm (Mean) | |
|---|---|---|
| Supine Pulse Rate | Standing Pulse Rate | |
| PF-05212377 30 mg | -0.4 | -0.7 |
| Placebo | 0.5 | 1.8 |
The pulse rate changes from baseline at Week 16/Early Termination (Visit 5) including supine pulse rate, and standing pulse rate. (NCT01712074)
Timeframe: Baseline and Week 16/Early Termination
| Intervention | bpm (Mean) | |
|---|---|---|
| Supine Pulse Rate | Standing Pulse Rate | |
| PF-05212377 30 mg | -0.8 | -1.9 |
| Placebo | 0.6 | 0.8 |
The pulse rate changes from baseline at Week 6 (Visit 3) including supine pulse rate, and standing pulse rate. (NCT01712074)
Timeframe: Baseline and Week 6
| Intervention | beats per minute (bpm) (Mean) | |
|---|---|---|
| Supine Pulse Rate | Standing Pulse Rate | |
| PF-05212377 30 mg | -1.4 | -0.3 |
| Placebo | 1.4 | 1.3 |
The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | -1.2 |
| Donepezil IR 10 mg | -1.2 |
The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 0.6 |
| Donepezil IR 10 mg | 0.4 |
The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method. (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Donepezil SR 23 mg | 2.6 |
| Donepezil IR 10 mg | 0.4 |
The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening). (NCT00478205)
Timeframe: Baseline and Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Donepezil SR 23 mg | 4.23 |
| Donepezil IR 10 mg | 4.29 |
The modified ADAS-Cog is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation. Subjects' scores represent the total number of errors made throughout the various tasks. The total number of possible errors is between 0-85. (NCT01658228)
Timeframe: Week 16
| Intervention | number of errors on a scale from 0-85 (Mean) |
|---|---|
| Donepezil Treatment Group | 13.2 |
| Placebo Treatment Group | 13.9 |
The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained. (NCT01658228)
Timeframe: Week 16
| Intervention | Words (Mean) |
|---|---|
| Donepezil Treatment Group | 7.4 |
| Placebo Treatment Group | 7.4 |
The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) was obtained. (NCT01658228)
Timeframe: Week 16
| Intervention | Words (Mean) |
|---|---|
| Donepezil Treatment Group | 45.6 |
| Placebo Treatment Group | 46.6 |
Number of participants who withdrew due to side effects. (NCT00227994)
Timeframe: Measured throughout the study
| Intervention | participants (Number) |
|---|---|
| Galantamine | 5 |
| Donepezil | 5 |
Score on Functional Independence Measure (FIM) motor score, where 7 indicates total assistance/complete dependence and 91 is complete independence (NCT00227994)
Timeframe: Measured at weeks 0 and 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline FIM | Week 12 FIM | |
| Donepezil | 49.4 | 87.4 |
| Galantamine | 47.1 | 73.1 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
The BDI-II is a 21-question multiple-choice self-report inventory test for measuring the severity of depression. Scores range from zero to 63; higher scores indicate greater depression. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the BDI-II scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the scores. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.022 |
| Intranasal Insulin 10 International Units | -0.019 |
| Placebo | -0.045 |
This is a visual, nonverbal test of learning and memory. Scores range from zero to 12; higher is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the BVMT-R delayed recall scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.027 |
| Intranasal Insulin 10 International Units | 0.059 |
| Placebo | 0.030 |
This is a verbal learning and memory test. Scores range from zero to 16; a higher number is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the primary analyses include the CVLT-II scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.082 |
| Intranasal Insulin 10 International Units | 0.021 |
| Placebo | 0.020 |
This test measures phonemic fluency. The test scores the number of words a participant can provide that begin with a specified letter within one minute, such that scores range from zero (worst) to an infinite number (better). Total score is sum of three 60-second trials. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the primary analyses include the COWAT scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.090 |
| Intranasal Insulin 10 International Units | 0.070 |
| Placebo | 0.021 |
This test measures executive functioning, concept formation, and cognitive flexibility. Scores range from zero to 16; higher is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include DKEFS correct sort scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.001 |
| Intranasal Insulin 10 International Units | 0.027 |
| Placebo | 0.002 |
Judgment of Line Orientation Test measures a person's ability to match the angle and orientation of lines in space. Scores range from zero to 30; higher is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include JLO data acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.031 |
| Intranasal Insulin 10 International Units | 0.047 |
| Placebo | -0.005 |
"The Rao-version of the PASAT evaluates processing speed, working memory, and basic addition skills. Scores range from zero to 60; higher is better. Herein we present 3-second PASAT results (PASAT-3). In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include PASAT-3 scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the SDMT." (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.372 |
| Intranasal Insulin 10 International Units | 0.363 |
| Placebo | 0.212 |
This task will be performed at five study visits. The SDMT is one of the most commonly used tests to assess processing speed in the MS population and is included in the Minimal Assessment of Cognitive Function in MS (MACFIMS). Higher scores reflect a better outcome (range 0 to 110). In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the primary analyses include the SDMTs acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the SDMT. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.145 |
| Intranasal Insulin 10 International Units | 0.207 |
| Placebo | 0.163 |
The sleep questionnaire asks subjects to report various aspects related to their sleep routine. Scores range from zero to 21; higher score indicates worse sleep quality. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the PSQIs acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.026 |
| Intranasal Insulin 10 International Units | 0.035 |
| Placebo | -0.045 |
FAMS is a self-reported health-related quality-of-life instrument for people with multiple sclerosis. Subjects rate six quality-of-life domains: Mobility, Symptoms, Emotional well-being, General contentment, Thinking/fatigue, and Family/social well-being. Scores range from zero to 176; higher scores indicate better health-related quality of life. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the FAMS scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.056 |
| Intranasal Insulin 10 International Units | 0.051 |
| Placebo | 0.240 |
An adverse event will be defined as any occurrence or worsening of an undesirable or unintended sign, symptom (or abnormal laboratory test), or disease temporally associated with the use of a medicinal product or intervention, whether or not it is considered related to the product/intervention. We report overall adverse events in the relevant section. Here, we report adverse events that led to study discontinuation. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Intranasal Insulin 20 International Units | 3 |
| Intranasal Insulin 10 International Units | 2 |
| Placebo | 1 |
Fingerstick blood glucose levels were monitored twice within the 90 minutes following the first dose administration of study drug for the first 15 participants. (NCT02988401)
Timeframe: At the baseline visit, monitored twice within the 90 minutes following the first dose administration of study drug
| Intervention | mg/dL (Mean) | |
|---|---|---|
| First timepoint | Second timepoint | |
| Intranasal Insulin 10 International Units | 95.8 | 92.2 |
| Intranasal Insulin 20 International Units | 97.8 | 88.4 |
| Placebo | 90.0 | 87.8 |
Mean value change (from baseline) in Disability Assessment in Dementia (DAD) across entire study period. DAD evaluates the basic and instrumental activities in daily activities of elderly people with dementia. Higher scores reflect better functioning. DAD ranges from 0 to 100. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | -0.77 |
| Placebo Control | -0.40 |
"Mean value change (from baseline) in Geriatric Depression Scale (GDS) across entire study period. The GDS ranges from 0 to 30. Scores of 0-9 are considered normal, 10-19 mildly depressed, and 20-30 severely depressed." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .084 |
| Placebo Control | .242 |
Mean value change (from baseline) in Neuropsychiatric Test Battery (NTB) across entire study period. The NTB included the following well known cognitive tests: Rey Auditory Verbal Learning Test (RAVLT), Controlled Word Association Test (COWAT), Category Fluency Test (CFT), WMS-R Digit Span, and Trail Making Part A and B. The mean value was comprised of the z score of each of these tests with all z scores in the direction of higher scores better functioning. Range -3 to +3. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .21 |
| Placebo Control | .17 |
"Total number of conversions from Mild Cognitive Impairment to Alzheimer's disease across entire 3 year study period. Conversion is determined, or defined, by a Clinical Dementia Rating (CDR) score of greater than or equal to one.~Composite rating ranges from 0 no symptoms of dementia to 3 Severe symptoms of dementia." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ladostigil Hemitartrate | 14 |
| Placebo Control | 21 |
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
50 reviews available for donepezil and Cognition Disorders
| Article | Year |
|---|---|
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Topics: Cognition; Cognition Disorders; Cognitive Dysfunction; Donepezil; Glycerylphosphorylcholine; Humans; | 2023 |
Fatigue in Alzheimer's disease: biological basis and clinical management-a narrative review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cognition Disorders; Cross-Sectional Studies; Donep | 2023 |
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interac | 2017 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Humans; Ind | 2018 |
A review of clinical treatment considerations of donepezil in severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; PubMed | 2018 |
Drugs for cognitive loss and dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cogniti | 2013 |
Emerging pharmacotherapy for cancer patients with cognitive dysfunction.
Topics: Antineoplastic Agents; Central Nervous System Stimulants; Cholinesterase Inhibitors; Clinical Trials | 2013 |
[Treatment of cognitive impairments in oncology: a review of longitudinal controlled studies].
Topics: Adult; Benzhydryl Compounds; Case-Control Studies; Central Nervous System Stimulants; Cognition; Cog | 2014 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Benzhydryl Compounds; Cognition Disorders; Cranial Irradiation; Donepezil; Humans; Indans; Me | 2014 |
Pharmacological interventions for cognitive decline in people with Down syndrome.
Topics: Acetylcarnitine; Adult; Antioxidants; Cognition; Cognition Disorders; Donepezil; Down Syndrome; Huma | 2015 |
Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.
Topics: Animals; Cholinergic Agents; Cholinergic Neurons; Clinical Trials as Topic; Cognition Disorders; Dem | 2016 |
Normal pressure hydrocephalus presenting as Othello syndrome: case presentation and review of the literature.
Topics: Aged; Antipsychotic Agents; Cerebral Ventricles; Cholinesterase Inhibitors; Cognition Disorders; Cor | 2008 |
Predicting cognitive decline in Alzheimer's disease: an integrated analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2010 |
Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Continuity of Patient Care; Donep | 2011 |
[Diagnosis and treatment of cognitive deficits caused by radiation in patients with brain tumours].
Topics: Animals; Biomarkers; Brain Neoplasms; Cholinesterase Inhibitors; Cognition Disorders; Cytokines; Don | 2011 |
Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.
Topics: Antidepressive Agents; Cholinesterase Inhibitors; Cognition Disorders; Depression; Donepezil; Drug T | 2012 |
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Lewy Body Disea | 2012 |
Cognitive impairment in ICU survivors: assessment and therapy.
Topics: Cholinesterase Inhibitors; Cognition; Cognition Disorders; Cognitive Behavioral Therapy; Critical Il | 2012 |
Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.
Topics: Binding Sites; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; | 2013 |
[Mild Cognitive Impairment: potential therapeutics].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Dopamine Agonist | 2002 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Nootro | 2003 |
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as To | 2003 |
Donepezil: a clinical review of current and emerging indications.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2004 |
Donepezil for vascular cognitive impairment.
Topics: Activities of Daily Living; Cognition Disorders; Dementia, Vascular; Donepezil; Humans; Indans; Noot | 2004 |
[Pre-clinical evaluation of effects of acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: PET study in conscious monkeys].
Topics: Acetylcholine; Acetylcholinesterase; Animals; Cerebrovascular Circulation; Cholinesterase Inhibitors | 2004 |
Mild cognitive impairment: a treatment at last?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepez | 2004 |
The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.
Topics: Aged; Basal Ganglia Diseases; Behavior; Cholinesterase Inhibitors; Clinical Trials as Topic; Cogniti | 2004 |
A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Hum | 2005 |
Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
Topics: Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorder | 2004 |
Clinical trials in mild cognitive impairment: lessons for the future.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Top | 2006 |
[Cognitive dysfunction and dementia associated with elderly diabetes].
Topics: Aged; Antihypertensive Agents; Brain; Cognition Disorders; Dementia; Diabetes Mellitus, Type 2; Done | 2006 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Nootro | 2006 |
Navigating patients and caregivers through the course of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Doub | 2006 |
Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepez | 2006 |
[Drug treatment for geriatric urinary disorders; current concept].
Topics: Aged; Aged, 80 and over; Amantadine; Cerebral Infarction; Cholinergic Antagonists; Cognition Disorde | 2006 |
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Hu | 2006 |
Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment.
Topics: Adult; Alzheimer Disease; Cognition Disorders; Disease Progression; Donepezil; Humans; Indans; Neuro | 2007 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
[Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans | 2008 |
Practical clinical use of therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition D | 2007 |
Diagnosis and management of vascular cognitive impairment.
Topics: Central Nervous System Agents; Clinical Trials as Topic; Cognition Disorders; Dementia, Vascular; Do | 2007 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognitio | 1996 |
Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Cost-Benefit Analysis; Disease Progression; Donepezil; | 1998 |
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Diso | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
Is the placebo control obsolete in a world after donepezil and vitamin E?
Topics: Cognition Disorders; Control Groups; Controlled Clinical Trials as Topic; Donepezil; Ethics Committe | 1998 |
An economic perspective on Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Combi | 1999 |
Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepe | 1999 |
Donepezil for mild and moderate Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Piperi | 2000 |
Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Cost of Illness; Donepezil; Female; Humans; Indans; Ma | 2001 |
86 trials available for donepezil and Cognition Disorders
| Article | Year |
|---|---|
Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil.
Topics: Alzheimer Disease; Cognition; Cognition Disorders; Donepezil; Humans; Neuropsychological Tests | 2021 |
A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Cognition Diso | 2018 |
Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome.
Topics: Adolescent; Adult; Brain; Child; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezi | 2019 |
Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults.
Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cognition Disorders; Cross-Over Studies; Donepezil; Do | 2013 |
[Clinical research of early intervention of modified shuyu pill in vascular cognitive impairment no dementia].
Topics: Aged; Cognition Disorders; Donepezil; Drugs, Chinese Herbal; Early Medical Intervention; Female; Hum | 2013 |
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2013 |
Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.
Topics: Activities of Daily Living; Alzheimer Disease; Analysis of Variance; Cognition Disorders; Donepezil; | 2013 |
Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Choli | 2014 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cognition Disorders; Donepezil; Double-Bli | 2014 |
Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Disease Management; Donepezil; Doub | 2014 |
Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cholinesterase Inhibitors; Cognition Disorders; Com | 2015 |
Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition | 2016 |
A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy.
Topics: Adult; Affect; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Cholinesterase Inhibitors; Cognition; | 2016 |
Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cognition; Cognition Disorders; Do | 2015 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinergic Agonists; Cholinestera | 2016 |
Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer's disease: the Osaki-Tajiri Project.
Topics: Aged; Alzheimer Disease; Art; Cognition Disorders; Combined Modality Therapy; Donepezil; Humans; Ind | 2008 |
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Donepezil; Female; Humans; Indans; | 2008 |
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Atrophy; Brain; Cerebral Ventricl | 2008 |
Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging.
Topics: Aged; Cerebral Cortex; Cognition Disorders; Donepezil; Double-Blind Method; Female; Humans; Indans; | 2009 |
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2009 |
Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Cross-Over Studi | 2009 |
Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Donepezil; Dose-Response Relationship, Drug; Drug | 2009 |
Donepezil delays progression to AD in MCI subjects with depressive symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Brain; Cholinesterase Inhibitors; Cognitio | 2009 |
Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Clinical Protocols; Cognition | 2009 |
The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Mapping; Cerebral Arteries; Cerebral Cortex; Cereb | 2010 |
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.
Topics: Adult; Aged; Aged, 80 and over; Amnesia; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D | 2010 |
Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cognition Disorders; Donepezil; Double-Blind | 2010 |
Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17.
Topics: Adolescent; Behavior; Caregivers; Child; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D | 2010 |
Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2011 |
Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial.
Topics: Activities of Daily Living; Adult; Cognition Disorders; Donepezil; Double-Blind Method; Down Syndrom | 2011 |
Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study.
Topics: Adult; Aged; Brain Mapping; Cognition Disorders; Donepezil; Female; Functional Laterality; Humans; I | 2011 |
Cognitive impairment and MS: searching for effective therapies.
Topics: Adolescent; Adult; Aged; Cognition Disorders; Disability Evaluation; Donepezil; Double-Blind Method; | 2011 |
The scopolamine model as a pharmacodynamic marker in early drug development.
Topics: Adult; Animals; Cognition Disorders; Disease Models, Animal; Donepezil; Dose-Response Relationship, | 2012 |
The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Combined | 2012 |
Goal setting and attainment in Alzheimer's disease patients treated with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Goals; H | 2002 |
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Donepezil; Drug Therapy, Combinat | 2003 |
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De | 2003 |
Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Cross-Over Studies; Don | 2003 |
Effects of donepezil on cognitive functioning in Down syndrome.
Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Dose-Response Relation | 2003 |
A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.
Topics: Adult; Cognition Disorders; Cross-Over Studies; Donepezil; Double-Blind Method; Female; Humans; Inda | 2004 |
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Fema | 2004 |
Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Double-Blind Met | 2004 |
Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs.
Topics: Aged; Antioxidants; Carcinoma, Small Cell; Cholinesterase Inhibitors; Cognition Disorders; Donepezil | 2005 |
Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Injuries; Cholinesterase Inhibitors; Cognition | 2005 |
Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer dementia.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Cognition Disorders; Cross-Sectional Studies; Donepezil | 2004 |
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorde | 2004 |
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cerebral Cortex; Cholin | 2005 |
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.
Topics: Capsules; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Dose-Response Relationship, Dru | 2005 |
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Cognition Disord | 2005 |
Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Brain; Brain Ischemia; Cholinesterase Inhibitors; Cognition Disorders; Demo | 2005 |
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort S | 2005 |
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Confidence Intervals; Donepezil; Double-Blind | 2005 |
Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Comorbidity; Cr | 2006 |
3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2006 |
Donepezil and vitamin E for mild cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Donepezil; Humans; Indans; Long-Term Care; Piperidines; Trea | 2006 |
Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life.
Topics: Adult; Affect; Aged; Anger; Brain Neoplasms; Cholinesterase Inhibitors; Cognition Disorders; Donepez | 2006 |
Verbal repetition in patients with Alzheimer's disease who receive donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezi | 2006 |
Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Blood Flow Velocity; Brain; Cerebral Cortex; Co | 2006 |
Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study.
Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cognition Disorders; Czech Republic; Donepezil; Double | 2006 |
Effect of donepezil on motor and cognitive function in Huntington disease.
Topics: Chorea; Cognition Disorders; Donepezil; Female; Humans; Huntington Disease; Indans; Male; Middle Age | 2006 |
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Chronic Disease; Cognition Disorders; Donepe | 2007 |
Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.
Topics: Activities of Daily Living; Aged; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Apolipoprotein | 2007 |
Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.
Topics: Aged; Aged, 80 and over; Antioxidants; Atrophy; Cholinesterase Inhibitors; Cognition Disorders; Done | 2008 |
A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Cross-Over Studies; Donepezil; Dose-Response Relatio | 2007 |
Cognitive predictors of donepezil therapy response in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Femal | 2007 |
Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
Topics: Aged; Cardiopulmonary Bypass; Cognition Disorders; Coronary Artery Bypass; Donepezil; Dose-Response | 2007 |
Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; | 2008 |
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Double-B | 2008 |
Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase I | 2007 |
No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia.
Topics: Adult; Brain; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors; Cognition Disorders; Diagno | 2007 |
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.
Topics: Aged; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Cognition Disorders; Disease Progr | 2007 |
Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study.
Topics: Aged; Antidepressive Agents; Cholinesterase Inhibitors; Cognition Disorders; Depressive Disorder; Do | 2008 |
A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Bipolar Disorder; Cholinesterase Inhibitors; Co | 2008 |
A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Double-Blind Method; Female; Humans; Inda | 2007 |
Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort S | 2008 |
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Topics: Adult; Aged; CADASIL; Cognition Disorders; Confidence Intervals; Donepezil; Double-Blind Method; Fem | 2008 |
Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepe | 1999 |
A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments.
Topics: Adult; Aged; Attention; Cognition Disorders; Donepezil; Female; Humans; Indans; Male; Middle Aged; M | 2000 |
Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Electromyography | 2000 |
Donepezil in the treatment of progressive supranuclear palsy.
Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Humans; Indans; Male; Middl | 2001 |
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.
Topics: Adult; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Cognition Disorders; Cross-Over Studies | 2001 |
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Donepezil; Dose-Response Relationship, Drug; | 2002 |
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Cross | 2002 |
118 other studies available for donepezil and Cognition Disorders
| Article | Year |
|---|---|
Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Cognitive Dysfunction; | 2022 |
A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment.
Topics: Aging; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Cognition Disorders; Donepezil; Drug Ev | 2020 |
Alpinia oxyphylla-Schisandra chinensis Herb Pair Alleviates Amyloid-β Induced Cognitive Deficits via PI3K/Akt/Gsk-3β/CREB Pathway.
Topics: Alpinia; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognition Disorders; Cy | 2020 |
5-N-ethyl Carboxamidoadenosine Stimulates Adenosine-2b Receptor-Mediated Mitogen-Activated Protein Kinase Pathway to Improve Brain Mitochondrial Function in Amyloid Beta-Induced Cognitive Deficit Mice.
Topics: Adenosine A2 Receptor Agonists; Adenosine-5'-(N-ethylcarboxamide); Alzheimer Disease; Amyloid beta-P | 2020 |
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain Chemistry; Cholinesterase Inhibito | 2020 |
Development and treatment of cognitive inflexibility in sub-chronic stress-re-stress (SRS) model of PTSD.
Topics: Acetylcholine; Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Done | 2021 |
The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Autophagy; Autophagy-Related Protein-1 H | 2021 |
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Canada; Cholinesterase Inhib | 2017 |
Clinical Pearls in Geriatrics.
Topics: Acetaminophen; Aged; Aged, 80 and over; Automobile Driving; Cognition Disorders; Cognitive Dysfuncti | 2017 |
A benzothiazole/piperazine derivative with acetylcholinesterase inhibitory activity: Improvement in streptozotocin-induced cognitive deficits in rats.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Avoidance Learning; Behavior, Animal; Benzothiazol | 2017 |
Systemic administration of donepezil attenuates the efficacy of environmental enrichment on neurobehavioral outcome after experimental traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries, Traumatic; Cerebral Cortex; Cognition Disorders; Dise | 2018 |
The effect of donepezil on the cognitive ability early in the course of recovery from traumatic brain injury.
Topics: Adolescent; Adult; Aged; Brain Injuries, Traumatic; Cognition Disorders; Donepezil; Female; Glasgow | 2018 |
Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Japan-Great Outcome of Long-term trial with Donepezil (J-GOLD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorder | 2018 |
Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Brain; Calcineurin; Calcineurin Inhibitors; | 2018 |
Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Aged, 80 and over; Altitude; Asian People; C | 2018 |
Studies of the Anti-amnesic Effects and Mechanisms of Single and Combined Use of Donepezil and Ginkgo Ketoester Tablet on Scopolamine-Induced Memory Impairment in Mice.
Topics: Acetylcholine; Acetylcholinesterase; Amnesia; Animals; Benzothiazoles; Biphenyl Compounds; Brain-Der | 2019 |
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhib | 2013 |
Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex.
Topics: Adenosine A2 Receptor Antagonists; Animals; Cognition; Cognition Disorders; Disease Models, Animal; | 2013 |
Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cholineste | 2013 |
Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism.
Topics: Acetylcholine; Animals; Autistic Disorder; Caudate Nucleus; Cholinesterase Inhibitors; Cognition Dis | 2014 |
Increased levels of plasma p3-alcα35, a major fragment of Alcadeinα by γ-secretase cleavage, in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid Precursor Protein Secretases; Biomarkers; Calciu | 2014 |
Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia.
Topics: Aged; Cognition Disorders; Dementia; Donepezil; Electrocardiography; Female; Heart; Humans; Indans; | 2014 |
Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.
Topics: Acetylcholinesterase; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Aza Co | 2014 |
The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Berberine; Brain; Cell Survival; Cogniti | 2015 |
Bone Marrow-Derived Endothelial Progenitor Cells Protect Against Scopolamine-Induced Alzheimer-Like Pathological Aberrations.
Topics: Adipose Tissue; Alzheimer Disease; Animals; Cell Movement; Cells, Cultured; Cognition Disorders; Cyt | 2016 |
Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorder | 2016 |
The Relationship Between Medial Temporal Lobe Atrophy and Cognitive Impairment in Patients With Dementia With Lewy Bodies.
Topics: Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Atrophy; Cognition Disorders; Do | 2015 |
Nootropic, neuroprotective and neurotrophic effects of phloretin in scopolamine induced amnesia in mice.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Animals; Antioxidants; Brain-Derived Neurotrophic | 2015 |
Efficacy of Donepezil for Cognitive Impairments in Familial Hypercholesterolemia: Preclinical Proof of Concept.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Discrimination, Psychological; Disease Mode | 2015 |
Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?
Topics: Alzheimer Disease; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cognition Disorders; Done | 2016 |
Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cholinesterase Inhibitors; Cognition; Cognition Dis | 2016 |
Sunitinib, a Clinically Used Anticancer Drug, Is a Potent AChE Inhibitor and Attenuates Cognitive Impairments in Mice.
Topics: Acetylcholinesterase; Animals; Antineoplastic Agents; Cholinergic Antagonists; Cholinesterase Inhibi | 2016 |
Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.
Topics: Animals; Behavior, Animal; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models | 2016 |
Donepezil: It is time to replace physostigmine in Anesthesiology.
Topics: Aging; Anesthesia, General; Anesthesiology; Anesthetics; Brain; Cholinergic Neurons; Cholinesterase | 2016 |
PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain.
Topics: Animals; Antineoplastic Agents; Brain; Cognition; Cognition Disorders; Disease Models, Animal; Donep | 2016 |
The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; | 2008 |
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo | 2008 |
Plasma urate and progression of mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Boston; Cognition Disorders; Confounding Factors, Epidem | 2009 |
Cracking the therapeutic nut in mild cognitive impairment: better nuts and better nutcrackers.
Topics: Alzheimer Disease; Biomarkers; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disord | 2009 |
Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Electroconvulsive Therapy; Female; | 2009 |
Cognitive performances of cholinergically depleted rats following chronic donepezil administration.
Topics: Acetylcholine; Analysis of Variance; Animals; Antibodies, Monoclonal; Behavior, Animal; Cholinestera | 2009 |
Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors.
Topics: Analysis of Variance; Animals; Anisoles; Brain; Cell Membrane; Cholinesterase Inhibitors; Cognition | 2009 |
Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect.
Topics: Aged; Aspartic Acid; Brain; Cognition Disorders; Dementia; Donepezil; Female; Humans; Indans; Magnet | 2009 |
Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Confounding Factors, Epidemiologi | 2009 |
Dementia: Does depression predict donepezil response in MCI?
Topics: Cognition Disorders; Dementia; Depression; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 2009 |
Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Aziridines; Benzodioxoles; Choline; Cog | 2010 |
Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain Mapping; Cholinesterase Inhibitors; Cognition Disorders; Coh | 2010 |
Effect of donepezil on the continuum of depressive symptoms, mild cognitive impairment, and progression to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Depressive Disorder; Disease Progre | 2010 |
Donepezil and concurrent sertraline treatment is associated with increased hippocampal volume in a patient with depression.
Topics: Adult; Alzheimer Disease; Atrophy; Cholinesterase Inhibitors; Cognition Disorders; Depressive Disord | 2010 |
Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2010 |
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
Topics: Alzheimer Disease; Caregivers; Cognition Disorders; Cost-Benefit Analysis; Disease Progression; Done | 2012 |
Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice.
Topics: Alzheimer Disease; Animals; Choline O-Acetyltransferase; Cognition Disorders; Conditioning, Psycholo | 2011 |
Relief of carotid stenosis improves impaired cognition in a rat model of chronic cerebral hypoperfusion.
Topics: Acetylcholine; Acoustic Stimulation; Analysis of Variance; Animals; Biogenic Monoamines; Brain Ische | 2011 |
Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cognition Disorders; Donepezil; Do | 2011 |
Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Cognition Disorders; | 2011 |
Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.
Topics: Amyloid beta-Peptides; Analysis of Variance; Animals; Butyrylcholinesterase; Cholinesterase Inhibito | 2011 |
Improvement of cognitive impairment following delayed CO encephalopathy.
Topics: Adolescent; Brain Diseases; Carbon Monoxide Poisoning; Cognition Disorders; Donepezil; Humans; Indan | 2011 |
Delusional parasitosis associated with donepezil.
Topics: Aged; Cognition Disorders; Delusions; Donepezil; Dose-Response Relationship, Drug; Ectoparasitic Inf | 2011 |
Unemployment in multiple sclerosis: the contribution of personality and disease.
Topics: Adult; Affect; Chi-Square Distribution; Cognition; Cognition Disorders; Cost of Illness; Cross-Secti | 2012 |
Is donepezil effective for multiple sclerosis-related cognitive dysfunction? A critically appraised topic.
Topics: Cognition Disorders; Donepezil; Humans; Indans; Memory; Multiple Sclerosis; Nootropic Agents; Piperi | 2012 |
Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: a pilot study.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Child; Cholinesterase Inhibitors; Cogniti | 2012 |
Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils.
Topics: Animals; Brain Ischemia; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Death; Cognition D | 2012 |
Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.
Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Cholinergic Fibers; Cholinesterase Inhibitors; | 2012 |
The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Behavior, Animal; Benzylidene Compounds; Cholinest | 2013 |
Comparison of functional and cognitive donepezil effects in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 2002 |
Donepezil for cognitive deficits following traumatic brain injury: a case report.
Topics: Adult; Brain Injuries; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Ma | 2002 |
A case series of D-cycloserine added to donepezil in the treatment of Alzheimer's disease.
Topics: Adolescent; Adult; Alzheimer Disease; Antimetabolites; Child; Cholinesterase Inhibitors; Cognition D | 2002 |
Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease.
Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dement | 2003 |
Cognitive decline in Down syndrome.
Topics: Adult; Age Factors; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Down Syndro | 2003 |
The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Hallucin | 2003 |
The impact of drugs against dementia on cognition in aging and mild cognitive impairment.
Topics: Adult; Aged; Aged, 80 and over; Aging; Cognition; Cognition Disorders; Dementia; Donepezil; Female; | 2003 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition | 2004 |
[A study of the effect of donepezil hydrochloride on cognitive function in patients with dementia of Alzheimer's type using WAIS-R].
Topics: Aged; Alzheimer Disease; Cognition Disorders; Donepezil; Female; Humans; Indans; Male; Nootropic Age | 2004 |
Donepezil for alcohol-related dementia: a case report.
Topics: Aged; Alcohol-Related Disorders; Cognition Disorders; Donepezil; Drug Administration Schedule; Human | 2004 |
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cognition Disorders; Donep | 2004 |
A case study in the treatment of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galant | 2004 |
The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes.
Topics: Adult; Analysis of Variance; Brain Injuries; Cognition Disorders; Donepezil; Drug Administration Sch | 2004 |
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Topics: Age Factors; Aging; Animals; Cognition; Cognition Disorders; Donepezil; Dose-Response Relationship, | 2004 |
Treating cognitive deficits in multiple sclerosis: are we there yet?
Topics: Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Memory; Multiple Sclerosi | 2004 |
[An interventional study on amnestic mild cognitive impairment with small dose donepezil].
Topics: Aged; Aged, 80 and over; Amnesia; Aspartic Acid; Cognition; Cognition Disorders; Creatine; Donepezil | 2004 |
Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Cholinesterase Inhibitors; Cog | 2005 |
Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Down Syndrome; Female; H | 2005 |
Searching for methods to detect, prevent, and treat Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepez | 2005 |
Mild cognitive impairment--no benefit from vitamin E, little from donepezil.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Cognition Disord | 2005 |
Drug may temporarily slow progression of mild cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Donepezil; Female; Humans; Indans; Nootropic Agents; Piperid | 2005 |
When the drugs don't work.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Piperidines; Tr | 2005 |
Cognition-enhancing effects of donepezil in traumatic brain injury.
Topics: Adult; Brain Injuries; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Female; | 2005 |
Mild cognitive impairment: to treat or not to treat.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Disease | 2005 |
Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Mapping; Cerebral Cortex; Cholinesterase Inhibitor | 2005 |
Clinical analysis of cognitive function in diabetic patients by MMSE and SPECT.
Topics: Aged; Brain; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition Disorders; Diabetes M | 2006 |
An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Amphetamines; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Ch | 2005 |
Donepezil-induced nightmares in mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Donepezil; Dreams; Female; Follow-Up Studies; Humans; | 2006 |
Donepezil treatment of topiramate-related cognitive dysfunction.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Fructose; Humans; Indans; | 2006 |
Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester.
Topics: Acetylcholine; Analysis of Variance; Animals; Behavior, Animal; Choice Behavior; Cognition Disorders | 2007 |
Alzheimer's drug helps brain function after radiotherapy.
Topics: Alzheimer Disease; Brain Neoplasms; Cognition Disorders; Donepezil; Humans; Indans; Nootropic Agents | 2006 |
Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury.
Topics: Adult; Aggression; Amantadine; Cognition Disorders; Conduct Disorder; Donepezil; Frontal Lobe; Human | 2006 |
Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping.
Topics: Animals; Attention; Cholinesterase Inhibitors; Cognition Disorders; Conditioning, Psychological; Don | 2006 |
In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Capsules; Cholinesterase Inhibitors; Cognition Disorders; Delayed-Action | 2007 |
"This is the kind of information we need".
Topics: Alzheimer Disease; British Columbia; Clinical Pharmacy Information Systems; Cognition Disorders; Don | 2007 |
Drug may slow brain shrinkage in pre-Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Cognition Disorders; Disease Progression; Donepezil; Humans | 2006 |
Posttraumatic stress disorder-like symptoms after treatment with acetylcholinesterase inhibitors.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Magnetic Res | 2007 |
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 2007 |
Is donepezil useful for improving cognitive dysfunction in bipolar disorder?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bipolar Disorder; Cholinesterase Inhibitors; Cognition D | 2008 |
Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats.
Topics: Animals; Behavior, Animal; Brain; Brain Ischemia; Choline O-Acetyltransferase; Cilostazol; Cognition | 2007 |
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.
Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Disease Mod | 2008 |
For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; I | 2008 |
Use of donepezil in the treatment of cognitive impairments of moderate traumatic brain injury.
Topics: Brain Injuries; Cognition Disorders; Donepezil; Humans; Indans; Male; Middle Aged; Nootropic Agents; | 2008 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Advertisements for donepezil. National policy needs to be set for prescribing of this drug.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Health Policy; Humans; Indans; | 1997 |
Advertisements for donepezil. Review of drug in Drug and Therapeutics Bulletin is uninformed.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Piperidines; Treatment Ou | 1997 |
Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Co | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car | 1998 |
Donepezil improves symptoms of delirium in dementia: implications for future research.
Topics: Aged; Alcohol Withdrawal Delirium; Cholinesterase Inhibitors; Cognition Disorders; Delirium; Dementi | 1998 |
Donepezil overdose.
Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Multi-Infarct; Donepezil; Drug Overd | 1999 |
Brain injury, cognitive impairment, and donepezil.
Topics: Alzheimer Disease; Brain Injuries; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans | 1999 |
The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Humans; | 1999 |
Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury.
Topics: Adult; Brain Injuries; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Humans; In | 2000 |
Hypnopompic hallucinations with donepezil.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; | 2000 |